67/129

69	62	වී		<i>5</i> 5	46	45	4.	35	29	28	27	23		73				
aqp37	aqp30	aqp28	aqp26	aqp23	agp14	agp13	aqp9	aqp3	aqp_4	aqp_5	aqp_6	eqp 9	agp 10	aqp_21	aqp 27	8		
PΙΥ	ΥSΗ	S.J.	GLY	Ę	E	: AG	Z.	PS	7	LPS	ञ	Z	AS	8	AS	Diversity		***
	.,,	28S=28T= 30S=371=4 6V=46E=4 7F=47Y=5 2P=521=5	.,,,,	L#R	E=34			3P=3S=9L =37D						,,,,,,	, ,	,,,,,,	Equivalence	
		<b></b> ,			*		(*)*(*)*							4		Total	Total (+) vs (-)	Prograsis
	. 4 ( > • • 6 >					(>,++)	(hetero-(-)		>*4:>*4		15****			*******		Total	Fotal (homo)	Prognosis
DY68	SY75	ST68.2		LR67.4	LW70.1	AA67	1771.60	PS88	6'99//	SS80 LL80.	1766.7	II80		GG86.7			Total	F70Q10095
					· · · · · · · · · · · · · · · · · · ·	.,,,,		77	, , ,	E(+)<(+)	. , , , , , , , , , , , , , , , , , , ,			*******	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	Stomach	{ otal (+) √s (-)	Prognosis
		.,				,,,,,			, ,	Eu-)>hetero		,				Stomach	Totai (homo)	Prognosis
1Y83.3	HS100	ST77.8		RR68.1	LM72.4	AG68.4	19720	PS69.4	LV67.7	LL100	ST67.7	IM75.2		DG67.7	2		Stomach	1000000
	.,,,,,	***************************************		Republi			A++10()		.,,,,,				,			Other	Total (+)	Prognosis
				Linetera (- Izritaria Rhetera na may (-			Yheisrozii	•				•	C			: Other cancers	Fotal (homo)	Prognosis
DY65.3	SY100	TT83.4		1867 20	LL70	AA65.3	177080	PS65.3	LL87.5	LS100, SS100	SS87.5	H100		DD97.5			Cither	Progress
	Hamunottesapy						no adjuvani therapy Y(+)×(-) immunipherapy Y(+)×(-)		no adjuvant therapy Lindown		no adjuvani therapy Science			no adjuvant trerapy D(+>(+)	( ·		(*) Vs(-)	Treatment Effect

U.S. Patent Application No. 10/681,352
Amendment After Allowance dated August 20, 2009
Reply to Notice to File Corrected Application Papers of August 11, 2009
Replacement Sheet

68/129

~`` ₩	117	316	109	107	106 6	සි	102	99	88	88		1		8 i	79	78	77	70 :			
80086	aqp65	aqp84	aqp77	aqp75	3qp74	aqp71	agp70	agp67	agp66	aqp57	aqp58	aqp55	aqp53	agp52	8qp47	aqp46	aqp45	aqp38	D <sub>O</sub>		-
AEG	73	en Ø	707	2	AES	ADKT	EQR	V	Ö	ADSV	5	LPR	်	SdJ	Fγ	 EV	Sa	ΑV	Diversity		·
		<b>.</b>	***	• • • •				¥V	660=68E= 671=66V		: 15 15	: 55P=55R	OF J	52P=52L	: F=Y	 	E=G	. A≖V	,,,,,	Equivalence	-
				•			,	V(+)>(-)	E(+)>(-)			**************************************				•			Total	Total (+) Vs (-)	Prognasis
				.,,,				heterozi zhomb Vheterozh umozi	Dhelarovi Phomo En etaroviron (214)	A 0170 - 4		10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0							Total	Total (homo)	Prognosis
AG67 8	VV66.5	EE66.5	RT69.7	LV69.6	AS800	AK 1000	GG68 10	W70 10	DE70.1	AA8470	LP67'20	LP1000	QQ66.5	LP68.2	FY68.2	EV68.2	EG67	VV69.4	)	₹otal	Prognosis
***************************************								V(+)>(-)	E(+)>(-)			***************************************		***************************************					Stomach	Totai (+) vs (-)	Prognosis
				• , •				fretarosi- istamo Vieterosi- amasi-j	Distance - Distance - Debuggio -			**************************************		***************************************	• • /		,		Stomach	Totai (homo)	Prognosis
FG76.1	LV68.5	EQ68.5	RT72.4	LV71.5	AE83.3	KT83.3	GR69.6	W720	DE7780	AS100	LP68,4	LR750	LQ68.5	LP77.8	FY77.8	EV77.8	EG68.6	VV71.7		Stomach	Progress
			***					V(+)×(-)	E(+)>(-)		P(+)>(-)			***************************************					Other	Total (+)	Prognosis
						Chetero ( phrana Shaterovno mov) (	Ehelero (- Johanne	Indianosi Interna Vietera ind Indiana	Distanci ( Informa Eleteranio monici		Unitero II- Jahono Phatero No Imoa(II)			**************************************					Other	Total (homo)	Prognosis
2000 (8000 0000	V64 9	EE64.9	RR82.7	£V66.4	AS100	AATDO	067270	IVETO	DEGTO	SV80	9.55d]	PR68.3	0.064.9	PP63.4	YY63.4	VV63.4	EG84.2	AV84.7		Other cancers	Progress
بدون ا		•		•				no adjuvant therapy VI+3*[] Chemotherapy VI+3*] Immunotherapy VI+3*[]	no adjurant therspy E(+)*() Chemotherapy E(+)*() Immunotherapy E(+)*()			0 % % F							Total	Tota! (+) vs (-)	Treatment Effect

	256	253	252	235	229	217	214	199	<del>1</del> 72					148		121		199				************	
	aqp224	aqp221	: aqp220	; aqp203	: agp197	. aqp185	agp 162	: agp167	agp140						aqp90	: :		aqp87		8		***************************************	**
All	e R	ð	Th	7	NS	=	ž	¥	ΑT		200	Ħ	AGS	7	=	ଫ୍ର		FLY		Diversity			,,
.,	· j		***					***								***						Equivalence	•
DQ71AKD												•••	•					•••		Total	vs (-)	Total (+)	Commercia
	2							2.11	,					,				. >		Fotal		Fregnosis Total (homo)	· fire and one
	QR70.1	QQ66.5	RR66.5	N67.5	NS68	1167.8	SS66.4	HH67	AA66.4	\$1.00.00 .00	೧೩೩೩೦	HQ71.4	GS74.4		166.5	GG66.5		FY72.1				: Total	2
DQ74AS(3	<b>(</b>				,,	, , ,		.,			,,,					,***				Stomach	Œ	Frogrosis otal (+) vs	Posterio
	-						· · · · · · · · · · · · · · · · · · ·	,,,,,		.,	. /				***					Stomach		Frognosis Total (homo)	· Posses
	QR72.4	HQ68.5	. HR68.5	; IV70.7	NS69.4	169.4	NS58.4	HR68.4	: AT68.4	2000	C 8988	QQ67.9	GS75.3		1168.5	GT68.5		LY72.1				Siomach	
							- 1												cancers	Other	Vs(-)	Total (+)	Character
							C					.,.					(-)-homo	Fhetero	cancers	Other Career	(homo)	Total	Contraction of
	RR70	QQ64.9	RR64.9	. VV66.9	NS65.3	1165	SS64.1	HH65.3	AA64.1	W(10).F	: 08870	: HQ71.5	: GS72.5		: 1154.9	GG64.9		FY7590		,	cancers	Other	
				•••						70 7 7		• • • •	••		in a si		¥(+)>(-)	<ul> <li>Immunotherapy</li> </ul>		Total		Total (+) vs (-)	of Orangania

## 0

# \*\*\*

ta constitue to the second	agp37	aqp30	aqp28	aqp26	aqp23	aqp14	aqp13	aqp9	aqp3	aqp_4	aqp_5	aqp_6	eqp 9	aqp 10	aqp_21	agp 27	ន		
	DΙΥ	ASH	18	GLY	50	2	AG	FLΥ	PS	ΕΛ	Sd1	ES	<b>***</b>	AS	p <sub>G</sub>	As	Diversity		
		Immunotherapy Hheteron Inomo Immunotherapy Yheteron-Thomo		and the second of the second s	***************************************			no adjuvant therapy thetero homozi-i immunotherapy thetero homozi-i		no adjuvant therapy t.(  Interes (tonno) no adjuvant therapy  Viumo inelera (+)	no adjuvani frerapy Phomo-hatero (-)	no adjuvant therapy Statetero (homb) ino adjuvant therapy. Thombo hefero (+)			no adjuvant therapy Di Prhetero (homo), no adjuvant therapy Chomo hetero (, ))		Total	Total (homo)	: Treatment Effect
	no adjuvant therapy YY(78.2), Chemotherapy DY(62.5)	intruncherapy HY(69.6)						Chemotherapy LY(64.5) Immunotherapy YY (63.9)	no adjuvant therapy \$5/78)	no adjuvant therapy VV87-8	immunotherapy PP62	ng adjuvant Iberapy T1878	,		no adjuvant therapy GG67 6			All cases	Treatment Erest
			Object of the second course of the second co	***************************************		***************************************		immunotherapy Y+p+i		no adjuvant therapy L(-1>(+)	no adjuvant therapy (L. P(+)	NS Start			no adjuvant therapy Dirayi+)		Stomach	Total (+) Vs (-)	Treatment Effect
TO DE LOCALITO DE	,	Immunotherapy Hireleto-/ ) homo Immunotherapy Yhetero-/-j.homo			***************************************					no adjuvant therapy Ni chetaro (homo: no adjuvant therapy Vhomo-thetero ( ) )	no adjuvant therapy Litetero +-), no adjuvant therapy Phomoshetero (+-)	no adjuvant therapy St schelaro (homo), no adjuvant therapy Thomochetero (1)			no adjuvant therapy Di Phetero (homo ino adjuvant therapy Chomo-hetero (Li)		Stomach	Total (homo)	Treatment Effect
	.,/**	HYI65.2)		******************	ž	ì		intriunatherapy Y(62-9)		no adjuvant fherapy VV92 8	no adjuvant therapy PP92.6	na adjuvant melapy 1192.6			no adjuvant therapy 0/492/6			Stomach cancer	Treatment Effect
	no adjuvant therapy Y(+ (=(-))							do adjurent therapy Y(+>+(-) Chemotherapy Y(+>+(-)	MI S(4)×(3)		no adjuvant therapy Live(+)		***************************************				Other cancers	Total (+) Vs (-)	Treatment Effect
	no adjuvant therapy Di- patero-homo, no adjuvant therapy Dhomo hetero-kij		A	engle date is a 7 right divination a market dispersion of the consideration of the second				Immunotherapy Fhetero (Jahorno no adjuvant therapy Thetero Iomozii) Chemotherapy Thetero Iomozii	no adjuvant therapy Pt. The terrorhomo ino adjuvant therapy Shomo hetero							· · · · · · · · · · · · · · · · · · ·	Other cancers	Total (homo)	Treatment Effect
Control Contro	ro adjuvant therapy YV (69.7)		Assessed the second of the sec		5	ģ.,, ~		ro adjuvant therapy LY751) Chemotherapy LY (658) Immunotherapy LY (681)	ro adjuvant therapy SS(68.8)							ļ		Other cancers	Treatment Effect

/0/

## 71111

aqp66	aqp65	aqp64	agp77	agp75	agp74		aqp71	aqp70	aqp67	aqp66	aqp5/	agp56	aqp55	agp53	aqp52	aqp47	aqp46	aqp45	aqp38	90		
AEG	V	EQ	RT	23	AES		ADKT	EGR	₹	OF	ADSV	F	LPR	ಎ	Sd1	Ţ	TV	EG	2	Diversity		
Immunotherapy Gheterox(-)>homo									no adjiwant therapy thetero (+) Chemotherapy thetero (+) from Immunotherapy thetero (+) from adjiwant therapy Vhetero (+) Fromo Chemotherapy Vhetero (+) fromo Immunotherapy Vhetero (+) fromo Immunotherapy Vhetero (+) fromo	no adjuvent therapy Dhetero ( ))-homo. Chemotherapy Dhetero ( ) homo. Immunotherapy Dhetero ( )-homo. Imagiliushi therapy Enetseo ( ) -homo. Chemotherapy Etelero ( ) -homo. Immunotherapy Etelero ( ) -homo. Immunotherapy	Immunotherapy Afomo (all survived) Af- ) Tratero		, , , , , , , , , , , , , , , , , , ,	***************************************						; Total	Total (homo)	Treatment Effect
Immunotherapy EG782)	***************************************								no adjuvam herapy (W79 8) Chemotherapy DE(62 1) Immunotherapy EE (60 3)	no adjuvant herapy EE(777) Chemcharapy DE(621) hamundherapy EE(603)	immunotherapy AA (100)		***************************************		V4503450035003500450345034503450345034503					, c	All cases	Treatment Effect
Immunot herapy E(-)>(+)	**************************************					,,,,,								e e e e e e e e e e e e e e e e e e e	document of the second		.,,,,			Stomach	Total (+) Vs (-)	Treatment Effect
									Chemotherapy Meteroxy, homo Chemotherapy Yesteroxy, homo	Chemotherapy Dhetero ( ) homo Chemotherapy Ehetero ( ) homo	Immunotherapy Vhetero (-)>hono			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	***************************************				Chemotherapy Altereroy Thoma Chemotherapy Vheteroy Thoma	Stomach	Total (home)	Treatment Effect
Chemotherapy AA 70 6 immunotherapy EG 80 8)					A CALL TOTAL CONTROL OF THE CONTROL OF THE CALL				Chematherapy W(65.1)	Chemotherapy DE(65 t)	Immunofferapy AA(100)	,	:		· · · · · · · · · · · · · · · · · · ·				Chemotherapy AV(65.2)		Stomach cancer	Treatment Effect
	3											8	4	,	***************************************		.,,,				Total (+) Vs (-)	Treatment Effect
ro adjuvani therapy Ahelero ((+))- homo			AND A REAL OF REALTH OF THE PARTY OF THE PAR						Chemotherapy hetero ( - ) i- homo Chemotherapy Vhetero (homo i-) -	Chemotherapy Dheterox(, )), homo Chemotherapy Ehetero (homos=(,)			***************************************	especial control of the control of t	openies seeman s			***************************************	no adjuvant fherapy V.) hetero-homo no adjuvant therapy Aforno hetero-i-i	Other cancers	Total (homo)	Treatment Effect
no adjuvant therapy AG(87.5)					operation and the second and the sec	Chenotherapy TT(59.9)	no adjuvent therapy	Chemotherapy VV(60 8)	Chemotherapy (V/59 1)	Chemotherapy DE(59.1)			A STATE OF A STATE OF STATE OF A		en productiva en caracterista				no adjuvant therapy AVI713)		Other cancers	Freatment Effect

121129

	ŭ.	1

	aqp224	aqp221	aqp220	aqp203	аф197	aqp185	aqp182	aqp167	aqp140	aqp130	aqp126	aqp125	agp116	aqp90	aqp89	адр87	Đ		
All	QR	귤	둦	<u> </u>	S	-	NS	ま	:: AT	QR	E E	AGS	₹		ହ୍ୟ	æ,	: Diversity		
,				***************************************						Immunotherapy Cheteropic (phomo Immunotherapy Pheterophomovic)						Immunotherapy Yhetero-homo (-)	: Total	Total (homo)	Treatment Effect
	N. N. ()	****			no adjuvant therapy SS(78)					Immunotherapy QH(75)						no adjuvani therapy FY(2,3) immunotherapy LY (71,2)		All cases	Treatment Energy
		V * * *			***************************************							.,,.	.,		- • ١, ١	immunuther apy F( )>(+)	Stomach	Total (+) Vs (-)	Treatment Effect
		r				· · · · · · · · · · · · · · · · · · ·										Immunotherapy A; Pittorna) Chemotherapy Fittorna-heliera (-)	Stomach	Total (homo)	Treatment Effect
					NIS SS(70)			,					e			Chemotherspy FF(813), Immunotherspy LY(081)		Stomach cancer	Freatment Effect
					no adjuvant therapy Syrvey ()								••				: Other cancers	Total (+) Vs (-)	Treatment Effect
		****			no adjuvant therspy N- thetero-homo no adjuvant therapy Shonto hetaro-k-					4 ********						no adjuvant therapy Fhetero ( Phomo	: Other cancers	Total (homo)	Treatment Effect
					no adjuvant therapy Ss(68.8)							no adjuvant therapy AS(73.7)	• • • •			no adjivent herapy F1(75) Y1(75)			Treatment Effect

73/129

	, <u></u>	DQ	B	DQ	DO	DQ
		Cancer in	Category	Metastases	Alcohol	Smoking
		Family		•		,
D	Diversity					
aqp_27	AS					
aqp_21	DG					
aqp 10	AS					
aqp 9	×	ere and exalle and exalled an exalled an exalled an exalled and exalled an ex				
aqp 6	S					
aqp 5	LPS					
aqp_4						
aqp_3	PS			*		
aqp9	ΥIF	,		,,,,,		
aqp13	AG					
aqp14	LW.			LL100,		ý•••
:		•	,,,,,,	LM23.20		
aqp23	Ę					
aqp26	GLY					
aqp28	ST					
aqp30	HSY			#		
aqp37	PY	••••		2715	****	**

4/1/29

***************************************			GG94.4, EG82.8 O		AEG	aqp86
		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		LV26,4, VV12.5	V	agp85
				EQ26.4 EE12.5.0	ďΩ	aqp84
	(n	RR100 RT22.5			RT	aqp77
					77	aqp75
					AES	aqp74
		#		***************************************	ADKT	agp71
					EGR	agp70
***************************************				211.031A,031A,031A,031A,031A,033A,033A,033A,	7	aqp67
***************************************		***************************************	The Contract of the Contract o		R	aqp66
***************************************	***************************************	control of the contro	entpersonantivaentivaentivaentivaentivaentivaentivaentivaentivaentivaentivaentivaentivaentivaentivaentivaentiv		ADSV	aqp57
					LP	aqp56
	Provide a communicación de la compansión de communicación	n estados e estados estados estados estados e estados e estados entre entre entre entre entre entre entre esta	Addition there was negative and depart of principles of each was bloom was recognized and department.	PR29.7 LR0.0	LPR	aqp55
				L026.4 QQ12.5 O	ΓØ	aqp53
***************************************			200		LPS	aqp52
					FY	aqp47
					EV	aqp46
	AV24 1 VV15 60			EE50, GG194 O	EG	aqp45
#	#				AV	aqp38
				•	Diversity	DQ
Smoking	Alcohol	Metastases	Category	Cancer in Family		
DQ	DQ	DO	DQ	DO		

	3	ann224	agp221	aqp220	aqp203	aqp197	aqp158	aqp182	aqp167	aqp140	agp130	aqp126	1	agp125	aqp166	agp90	aqp89	aqp87	DQ			Fig. 75
All survived	THE TOTAL PROPERTY OF THE PROP	2	F	풌	7	NS	<b>—</b>	ZS	贡	AT	9	£		AGS	Z	<u>-</u>	GT	FLY	Diversity			
	ere de merco escolar con escolar con escolar merco escolar con escolar con escolar con escolar con escolar con	ma)punoun un oun outrour outrour un oun outrour	HQ26,4, QQ12.5 O	HR26.4, RR12.5 O	**		The second contract c	NS26.8, SS12.2 O	والمروع في مروع والمراج والمعاط والمعاط والمعاط والمعاط والمواط والمواط والمعاط والمعاط والمعاط والمعاط والمعاط	AT26.8, AA12.2 O						T26.4, II12.5	GT26.4, GG12.5			Cancer in Family	DQ	
		***************************************			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,				الما المارية في المارية الماري المارية المارية	***************************************	#									Category	DQ	
	QR23.2 O	RR100			VV32, II22.2	#	manan anjananan antan antan antan antan antan anta	THE THE TAX AND TH				•	0	SS100 AA20	II100, IV23.2			YY50 LL20 O		Metastases	8	
			29.46										e guide la la vi		N. 100.					Alcohol	DQ	
		mrandin amran amran amran amran.				DI66.7 DD39.1.O	***************************************	***************************************	estados de como cados estados de como	***************************************			KA & galasi		an en					Smoking	DO	

76/129

පිය	80	78		72	69	58		57	53	34	28	26	19	74	12	4	-16	Nucleic Acid	***************	DR
N	N		****;***;***	 er	c.a	6		~	2	3			2	, , , , , , , , , , , , , , , , , , ,	Ćn.	۵	ပ	No. of Diversity	****	
			,							,,,,,,,								Total	***************************************	10:3
, , ,			rcecroec	-000/000p					of a successful to deep defendence of the	,	hCACeGAG						aGCGaGCG>	Stomach	enja enverana enverana enverana enverana	and the real section of the section
,	71					eGAGaGCU eGAGaGCU	dGAUdGAU	dGACdGAU>	A to a label of the second	*******								Other cancers	e an reference annotes	
•		Chemotherapy: yUACyUAC> yUAUyUAU		no adjuvant therapy:		no adjuvant therapy: aGCCaGCC>aCGUaGCU. Chemotherapy: aGCUaGCU. aGCGaGCG. aGCCaGCU>aGCGaGCU			***************************************	••••					Immunotherapy: kAAAkAAA>kAAGkAAG> kAAAKAAG			Treatment Effect	All 0888	
			Chemotherapy: rCGGrCGG+rCGGrCGG, rCGCrCGG+rCGCrCGC	no adjuvant therapy: rCGCrCGG>rCGGrCGU	no adjuvant therapy:				ende mesende une mile mesen mesende mesende mesendes mesendes mesendes mesendes mesendes mesendes de constitue						Immunotherapy: kAAAkAAA>kAAGkAAG> kAAAkAAG			Treatment Effect	Stomach Cancer	***************************************
		Chemotherapy:	************	.,			Chemotherapy agccagcu, agccagcu-agccagcu-agccagcu	dGACdGAU, dGACdGAC, dGAUdGAU	and the state of t	no adjuvant therapy: gCAAqCAA> gCAAqCAG					no adjuvant therapy: kAAAkAAG>kAAGkAAG			Treatment Effect	Other cancers	AND EXCHANGE TO SECURE A COMMENT OF COMMENT OF SECURE AS

217	206		82	179	చేర్టల ల	iŝ.	152	345 5	117	123	<b>3</b>	ğ	Ö	99	Nucleic Acid		R
 N	· · ·			~	2		2	2	N	2	 N	ı	2	2	No. of Diversity		•••
	```.		••••	}····				,,			,	aGCAaGCC>			Total		: (013)
							***************************************			****	***		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		Stomach		1.0
•••		: tAGCMAUG	tACAmAUG>				***************************************								Other cancers	والمساورة	
				3		no adjuvant therapy: rCGGrCGG> rCGArCGA									Treatment Effect	All cases	
															Treatment Effect	Stomach Cancer	
						no ad rCGA	<b>:</b>						no adjuvant therapy: vGUGvGUG, vGUAvGUG> vGUAvGUA		Treatment Effect Treatment Effect	Other cancers	

78/129

1/0/1

	No of	Cancer in Family	Alcohol	Metastases	Smokina
Acid	Diversity	Carlocallitaling	אַכטונס		Ringolsto
	ယ				
4	ယ				
12	5				- 4
4	ఢు				
19	2				
26	5				
28	4		eGAGeGAG(55.6),		
		P	eGAAeGAG(0),		
			eGAAeGAA(16.7)		
34	ω				
<u> </u>	2		•••		
57	7				
58	6	STATE OF THE STATE			
69	ధు				
72	ري.	rCGGrCGU(50),			
		rCGCrCGG(40), rCGCrCGC(0)			,
78	ω				
90	2				
ຮີ	<b>'</b>				

79/129

•

DR	÷		***************************************	**************************************	
Nucleic Acid	No. of Diversity	Cancer in Family	Alcohol	Metastases	Smoking
95	2				
				vGUUvGUU(42.9)	••••
<u>0</u>	2				
10x	ယ				
100 000	N				
112	N				
117	2				
145	2				
152	2				
166 6	 				
169	2				
179	2				
181	ယ				
206	2				
747	····				

DR.		Total			Allouspe	Stomach Cancer
Nucleic	No. of	Total	Stomach	Other cancers	Treatment Effect	Treatment Effect
-29	***************************************					
-23	2					no adjuvant therapy: pCCUpCCU>pCCCpCCU, pCCCpCCC
-15	2					Same curve as DQ_23 pCCUpCCU>pCCCpCCC, pCCCCpCCC
DQNP19	2		Summer su			
DQNP21	ഫ			IACGIACC, IACGIACG>IACCIACC		
DQNP25	2		,		7	
DQNP27	2				Immunotherapy: vGUAvGUG, vGUGVGUG>vGUAvGUA	
DQNP35	2					
DQNP38	ω			aGCAaGCG>aGCGaGCG		
DQNP47	w					
DQNP48	2		to d			
DQNP49	ယ					,
DQNP57	ග		,			
DQNP62	2		,	nAACnAAC, nAACnAAU>nAAU		
DQNP72	2		.,,,,,,			
DQNP77	44			HACCIACG,		
DQNP78	2			VGUAvGUG, VGUGVGUG> VGUAVGUA		
DQNP91	2					
DQNP93	Ν.		, , , • •			
DONP94	2					

81/129

뮸		Total				
					All cases	
Nucleic	No. of	Total	Stomach	Other cancers	Treatment Effect	.,
Acid	Diversity				******	
DQNP118	2					
DQNP135	w					
DQNP140	4					
DQNP147	2					
DQNP150	2					
DQNP154	2					
DQNP169	2					
DQNP191	2				~,,,,	
DQNP210	2					
DQNP213	2					
DQNP215	2					
DQNP218	2					
DONP235	2					

82/129

Cancer in Alcohol Metastases Smoking  Family  InAACnAAC(54.7), nAACnAAU(59.8),  InAACnAAU(39.1)  InAACnAAU(39.1), rCGrCGG(59.8),  InCGArCGA(39.1), rCGrCGG(59.8),  InCGGrCGG(54.7)  InUGINUG(31.8)	0. 100. 100. 100. 100. 100. 100. 100. 1				***************************************	2	DQNP94
Cancer in Alcohol Metastases Family  Light Metastases  Family  Light Metastases  Lig	mer energen over novement er er er er energen over novement er er er er en en novement en er en en en en en en	anderskan seeden de someten de transmente de transmente de transmente de transmente de transmente de transment	***************************************	***************************************	***************************************	2	DQNP93
Cancer in Alcohol Metastases Family		ICUGICUG(39.7), ICUGIUUG(26.8), IUUGIUUG(31.8)				2	DQNP91
Cancer in Alcohol Metastases Family			(*)			2	DQNP78
Cancer in Alcohol Metastases Family					Chemotherapy: rAGGrAGG>rAGArAGG, rAGArAGA	4	DQNP77
Cancer in Alcohol Metastases Family	rCGGrCGG(54.7)		***************************************		rCGGrCGG, rCGArCGG>rCGArCGA		
in Alcohol Metastases	rCGArCGA(39.1), rCGrCGG(59.8),		*****		The Same curve with DQ19	2	DQNP72
in Alcohol Metastases	de control					2	DONP62
in Alcohol Metastases					*****	G	DONP57
in Alcohol Metastases						ယ	DQNP49
in Alcohol Metastases					34.7	2	DQNP48
in Alcohol Metastases				186.00	.,	ယ	DQNP47
in Alcohol Metastases					Chemotherapy: aGCAaGCG>aGCGaGCG	చ	DQNP38
in Alcohol Metastases			*****			2	DQNP35
in Alcohol Metastases				,		2	DQNP27
in Alcohol Metastases					. ,	2	DQNP25
in Alcohol Metastases					no adjuvant therapy: IACCtACG>!ACAtACG	ယ	DQNP 21
in Alcohol Metastases	nAACnAAC(54.7), nAACnAAO(59.8), nAAUnAAO(39.1)				no adjuvant merapy: nAACnAAC, nAACnAAU> nAAunAAu		PUNDU
in Alcohol Metastases					-	2	-15
in Alcohol Metastases						2	-23
in Alcohol Metastases						***	-29
Alachartage	Resource		YEO!EO!	Family	Tradillets Clieve	Diversity	Acid
			Maskal		Other cancers	No of	Nustaia
							DR.

83/129

DQNP235   2	DQNP218 2	DQNP215 2	DQNP213 2	DQNP210 2	DQNP191 2		DQNP154 2	 DQNP147 2	4	DQNP135 3	ļ	Diversity		
									no adjuvant therapy: aGCCaGCC>aCGUaGCU Immunotherapy: tACCaGCU>tACCaGCC		0.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.0	Freatment Effect	Incers	***************************************
	****							 6.694.694				Family	)	Č
				ICUCICUC(50), ICUCICUG(18.6), ICUGICUG(22.5)			2		TACCIACC(50), IACCIACU(21.3), IACUIACU(20.5)			Aiconoi		
		LCUUICUU(47.8), ICUGICUU(24.5), ICUGICUG(32.1)	ICUCICUC(32.6). ICUCICUU(27.1), ICUUICUU(34.4)			dGACdGAC(32.6), dGACdGAU(27.1), dGAUdGAU(34.4)		ICUCICUC(47.8), ICUCICUU(24.5), ICUUICUU(32.1)		dGACdGAC(32.6), dGACdGAU(27.1), dGAUdGAU(34.4)		Metastases		
												omoking		***************************************

### 84 / 129

DP		Total		\$			•
					All Cases	Stomach Cancer	Other cancers
Nucleic Acid	No. of Diversity	Total	Stomach	Other cancers	Treatment Effect	Treatment Effect	Treatment Effect
98	2	All same with the survival curve					
107	2	All same with the survival curve			-		
118	2	All same with the survival curve					
167	2	All same with the survival curve					
179	2	All same with the survival curve					
***************************************			***************************************				
************		All NS					

Fig. 85

Position	······	Div	erse An	ino Acid	<u></u>		no adjuvant therapy	Chemotherapy	Immunotherapy	
_29	M				1		М	M	M	
_28	M						M	M	M	
_27	٧						V	V	V	
26	Ĺ						Ĺ	Ĺ	<u> </u>	·
_25	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~						ā	Q	ā	<del> </del>
24	<del>~~~~</del>						<del>-</del>	V V	<del>                                     </del>	<del> </del>
	<u>`</u>								Š	<del></del>
-23							5	Ş		
22	<u>A</u>						Ą	A	A	ļ
_21	A P						A P	A P	A P	ļ
_20						************	β	P	Ρ	<u> </u>
19	Q						R	R	Ŕ	
18	Ť						T	Ţ	T	
17	Λ						V	V	V	
_16	Α						A	A	A	
15	£.						L.	L	L	
_14	Ŧ						T	T	T	1
13	A				1		A	A	A	
12	į.						L	Ĺ	l l	1
	L.						Ĩ.	Ĭ.	i i	1
_10	M						М	M	M	1
9	Λ '*'						v v	V V	T Ÿ	<b>†</b>
8								***************************************	+	<b>+</b>
	<u>_</u>						<u> </u>	<u> </u>	ļ	
7	<u>L</u>						<u>L</u>	<u>L</u>	<u> </u>	<b></b>
6	Ţ						Ţ	Ţ	Ţ	ļ
5	S						5	S	s	
4	<u> </u>						V	V	V	
_3	V						V	V	V	
2	Q						Q	Q	Q	
1	G						G	G	G	
1	R						R	R	R	
2							Α		A	
<u>2</u> 3	<u>А</u> Т						<u>A</u> T	A T	A T	
4	þ						P	P	P	·
5	E						£	È	E	·
6	N						N	N	T N	
7	<del>'\</del>						Ÿ	Ÿ	†	<del> </del>
8	~~~~~~~	V					L or V	L or V	LorV	<del></del>
9	L F	Н	Y							
9	r	m	Ŷ				0	()	0	DP8 LV and
									ļ	DPF
10	Q						Q	Q	Q	4
11	g	L					Gort	Gort	Gort	<b></b>
12	R						R	R	R	
13	Q E						Q E	Q E	Q E	
14	E						E	E	<u> </u>	
15	C Y						C Y	C Y	C Y	
16	Y						Y	Y	Y	
17	A						A	A	A	
18	A F						A F	A F	F	
19	N						N G	N G	N	1
20	N G					***************************************	G	G	N G	
21	Ť					••••••	T	Ť	T	1
22	à						T Q	T Q	Ī Q	1
23	Ř						Ř	Ř	+	+
24	F						F	F	R F	1
25							<u> </u>	<u> </u>		<b> </b>
45	<u>L</u>						L.	<del> </del>	L E	<del> </del>
26	E						E R	ļ <u>Ē</u>	<u> </u>	<b></b>
27	R						ĸ	E R Y	R	<b></b>
28	Υ	L	L	L	1		Y	<u> </u>	Υ	1

Fig. 86

Position		Di	verse A	mino A	id	••••••	no adjuvant therapy	Chemotherapy	Immunotherapy	
29	1	·		·			1	<b>1</b>	}	
30	Y						Y	Y	Y	
31	N						N	N	N	
32	R									
33	R						<b>R</b>	R E	R E	
34	Ē						W S	Ē	Ē	
35	E	L	Ÿ				()	()	()	
36	Ä	V					A or V	A or V	ÄV	
37	R	······					R	R	R	
38	F						F	F	<u> </u>	
39	D						D S	D	D	
40	S							S	S	
41	D						D	D	D	
42	V						V	V	V	
43	G						G	G	G	
44	E						ш	ε	E	
45							۴	F	F	
46	R						R	R	R	
47	Α						Α	А	A	
48	V						٧	V	V	
49	Ť						Ť	Ĩ	Ť	
50	ε						£.	E	Ε	
51	L						L	Ĺ	L	
52	G						G	G	G	
53	R						R	R	R	
54	Р						P	P	P	
55	A	n	Ε				AD	()	Ó	
56	A	D E					()	Ö	ΰ	
57		Ē						DE DE	······································	
58	Ÿ						<del></del> \$	Ÿ	\\\\\\	
59	W						W	Ŵ	Ŵ	
60	N						N	N N	N	
61	ន្ទ						Š	S Q	<u>S</u>	
62	Q						Q	Ġ.	9	
63	K						K	K	K	
64	D						Ω	D	D	
65	F	1	L				IL.	lorL	lort	
66	L						L	<u> </u>	<u>L</u>	
67	E						ш	E	E	
68	E						E	E E or K	E	
69	Æ	K					EΚ	€orK	E or K	
70	R						R	R	R	
71	Α						Α	A	А	
72 73	V						V	V	V	
73	p						Р	P	Á	
							<u> </u>		<del></del>	
74 75	D R						D R	D R	D R	<b></b>
76	<u></u>	M	V	<b></b>			(1	()	IM	<b></b>
77	Ċ		·····				ಎಂ	Č	Č	
78	R						Ř	O C R	R	
79	Н						Н	H	H	
13	17							F1 (4	***	<del> </del>
80	N						N	Ŋ	N	
81	Y						Y	Ϋ́	Ä	
82	E						m,	€ .	E	
83	L						L	L	Ļ	
84	D	G G					00	DG	0	ļ
85	E	G					()	EG	()	

Fig. 87

Position		Di	verse A	mino Ad	zid		no adjuvant therapy	Chemotherapy	Immunotherapy	
86	A	P				T	()	()	()	1
87	M	V		Ī			Ö	ΜV		
88	7						Ť	Ť	<u> </u>	
89	L						L	l,	L.	
90	Q						Q	Q	Q	
91	R						R	R	R	
92	R						R	R	R	
93	V						V	٧	V	
94	Q						Q	Q	Q	
95	P						Ρ	P	P	
96	K	R					()	0	()	
97	V						٧	У	V_	
98	N			-		_	N	N	N.	
99	V						V	V	V	
100	S						S	S	S	_
101	P						þ	p,	Р	
102	S						S	S	\$	
103	K					I	K	ĸ	ĸ	
104	K					T	K	K	К	
105	G			I		T	G	G	G	1
106	P						9	Р	Р	
107	L						L	Ļ	Ł.	
108	Q						a	Q	Q	
109	Н						Н	Н	H	
110	Н						H	Н	H	
111	N						N	N	N	
112	L					1	Ĺ	L	<u>L</u>	
113	L.						L.	<u>L</u>	£	T
114	~~~~						V	V	V	
115	C						С	C	C	
116	Н						Н	Н	Н	
117	V						V	V	V	
118	T					1	Ť	Ť	T	
119	D						D	Ö	9	
120	F						F	F	F	
121	Y						Y	Y	Y	
122	P	***************************************				<b>†</b>	P	р	P	
123	G					<b>†</b>	G	G	G	
124	S					<u> </u>	S	S	S	·
125	<u>-</u> -					†	1		Ī	·
126	Q					İ	a	Q V	i Q V	
127	Q V					İ	a V	Ÿ	V	
128	R						Ŕ	Ŕ	Ŕ	
129	W						W	W	Ŵ	
129 130	F						W F	W F	W F	
131	— <u>i</u>		<b></b>	1		·	i i	Ĺ	L	·
132	Ñ		·····	<b> </b>		<b></b>	Ñ	Ň	N	·
133	<del>'(</del> G		<b></b>	<b> </b>	<b></b>	<b>†</b>	Ğ	G	Ğ	
134	Q Q			<b> </b>		1	ä	Ö	ñ	+
135	Ē		· · · · · · · · · · · · · · · · · · ·			<b></b>	<u> </u>	Q E	Q E	· ·····
136	Ē			1			H H	€	Ë	+
137	Ť		<b></b>	<b></b>		<b>†</b>	Ť	Ť	Ť	1
138	A					-	Ā	À	À	<del> </del>
139	G					1	G	G	G	<del> </del>
140	$\tilde{v}$					1	v	V	ν	<b>-</b>
	~~ <del>``</del> ~~			<b></b>		<del> </del>	~~~~~~	v v	Ž	
4.4 1	×		L	1		ļ		· · · · · · · · · · · · · · · · · · ·	ļ	
141				1 :	1	E .	C	Q	C C	E
141 142 143	S						S	S T	5 T N	

Fig. 88

Position	•••••	Di	verse A	mino A	id	***********	no adjuvant therapy	Chemotherapy	Immunotherapy	
145	L	F	I				L	Į.	L.	
146	ī						1	1	***************************************	
147	Ŕ						Ŕ	Ŕ	Ŕ	
148	N	·					N	N	N	
149	G						G	G	G	
150	ă						ä	Ď	Ö	
151	W						W	W	<u>W</u>	
152	T						T	T T		
	F	ļ							<del>-</del>	
153							F	E		
154	Q	ļ	ļ				Ğ	<u> </u>	Ğ	
155										
156	L						LL	<u> </u>	L	
157	V						٧	V	٧	
158	M						M	М	М	
159	L						L	<u>L</u>	L	
160	E						E	E	E	
161	M						M	M	M	
162	T		L				Ŧ	Ţ	Ť	
163	P						۵	þ	P	
164	Q						Q	Q	Q	
165	Q		I				Q	Q	a	
166	G						G	G	G	
167	D						מ	Ð	a	
168	V						V	٧	У	
169	Ý						Ý	Ŷ	Ÿ	
170	Í	T					()	()	Ó	
171	Ċ	<del> </del>					č	č	č	
172	Q		·····				Q	ă	Q	
173	Ÿ	<b></b>	<b></b>				~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	<del>-</del>	
174	Ě	<b></b>					Ě	Ě	Ě	
175										
	H	ļ					H	H	H +	
176		ļ					Ţ	Ţ	Ţ	
177	S	ļ					S	S	S	
178	<u></u> _	M					LM	<u>()</u>	<u> </u>	
179	D						D	Ŋ	D S	
180	S						\$	S	S	
181	P						p	p	P	
182	V						V	V	٧	
183	Ŧ						Ť	Ţ	Ť	
184	V						V	V E W	γ	
185	E W						É	E	E	
186	W						W	VV	W	
187	K				L		K	K	K	
188	Α						Α	A	Α	
189	Q						Q	Q	Q	
190			T				·		~~~~~	
191	S D S		T				S D S	D S A R	5 D S A R	1
192	S	·	T				S	S	\$	1
193	A		<b>1</b>				A	A	A	
194	R	<b></b>	<b> </b>				A R	R	R	<b></b>
195	s	<b></b>	<b></b>				\$	s s	S	<b></b>
196	ĸ	<b></b>	<b>!</b>				K	ĸ	ĸ	
197	T	<u> </u>					T	Ť	Ť	
198	Ļ		<b></b>				L.	į.	Ĺ	
199	Ť	<b></b>	<b></b>				Ť	Ť	Ť	
		<b></b>								
200	G	ļ	ļ		ļ		Ģ	Ğ	Ğ	
201	Α				ļ		Α	A	A G G	
202	Ğ						Ğ	G G	<u> </u>	
203	G	<u> </u>	L	L	L		G	G	G	1

89 / 129

Fig. 89

Position		Diverse Am	ino Acid	no adjuv thera	ant Py		
204	۴			F	F	F	
205	V			V	V	V	
206	L.			L.	Ĺ	L	
207	G			G	G	G	
208	L.			L.	L.	L.	
209				1	<b> </b>	1	
210	1			}	1	1	
211	C			С	C	С	
212	G			G	G	G	
213	V			V	V	V	
214	G			G	G	G	
215	1			1	}	1	
216	È			F	F	F	
217	M			M	M	M	
218	Н			Н	Н	Н	
219	R			R	R	R	
220	R			R	R	R	
221	S			S	S	S	
222	K			K	K	К	
223	K			K	K	K	
224	V			V	V	V	
225	Q			Q	Q	Q	
226	R			R	R	R	
227	G			G	G	G	
228	S			S	\$	\$	
229	A			A	A	A	

"or" - expected to be the same antigen

Fig. 90

Position		Di	verse A	mino Ac	ad		no adjuvant therapy	Chemotherapy	Immunotherapy	
32	M	·					M	M	M	
31	S						M S	M S	M S	
30	W		·····				W	W	w	
_29	K						K	K	<del>K</del>	
	K							ĸ	ĸ	
_28 _27		S					K			
	Α						()	Ω	ψ	
_26	L						L	<u>L</u>	<u>L</u>	
25	R						R	R	R	
24	Р						}	<b> </b>	P	
_23	Р						p	P	P	
_22	G						G	Ģ	G	
_21	D	G			**********		GG	()	GG	
20							L	L L	L	
19	R	<b></b>	·····				Ř	Ř	Ř	
_18	A	V	·····	·			()	0	()	
		<u>`</u>	<b></b>							
	A						A	<u> </u>	A	
_16	T V	ļ					Ţ	Ţ	Ţ	
_15	V						V	V	V	
14	T						T	T	T	
14 13	T L						L	L	L	
_12	M						M	М	M	
_11	L	·					L	L	L	
_10	Α	S					0	()	()	
9	· · · · · · · · · · · · · · · · · · ·	M	······				······	()	()	
									······	
8	<u></u>					~~~~~	<u>L</u>	L		
7	S						S	S	S	
_6	S	T P					TT	()	TT	
_5	L	Р	S				()	()	qq	
4	L	V					VV	()	W	
3 2	A E						A E	<u>A</u> E	A E	
2	Æ						Æ	E	E	
1	G				***************************************	***************************************	G	G	Ğ	
1	R				~~~~	***************************************	Ř	R	Ř	
2	Ď						D	Ď	<u>D</u>	
3	P	\$					SS	PS	PorS	
***************************************					***************************************					
4	Р	ļ	ļ				P	P		
5	E						E D	E D F	P E	
6 7	D F						D	D	D F	
7	F						F		F	
8	V						V	٧	V	
9	£	L	Y				0	LY	YY	DQ3 PS is same as DQ9 L
10	Q						Q	Q	Q	
11	F						۴	F	<u> </u>	
12	F K						K	K	K	
13	A	G	·····	·			0	AA	GG	<b></b>
14	Ĺ	M	<b></b>				L or M	L or M	LM	
15	—— <u>—</u>	141						C 01 181	FIVI	<del> </del>
	C Y		ļ	ļ			C Y	C Y	C Y	
16	<u> </u>						<u>Y</u>	Y	<u> </u>	
17	F						F	F	r T Z	
18 19	Ţ						T N	T N	Ţ	
19	N						N	N	N	
20	G						G	G	G	
21	T E	I	T				T E	T E	T E	
22	F						E	£	F	
23	Ĺ	R	<b></b>				LR	L or R	RR	
<u>23</u> 24	Ÿ	<del> '</del>	<b></b>	·	ļ		V	V V	<del>\</del>	
25	<u></u>	ļ					<u>V</u>	R	Ř	
	R	ļ	<b></b>	ļi			R	K	<u> </u>	
26	G	L	YY				<del>0</del>	<del></del>	· · · · · · · ·	
27	V	1	l .	1			V	V	·	

Fig. 91

Position		Cinco	A	wino	Anid		no aditiont thorony	Chamatharrasi	Lineaumatharani	1
28	S	T	SC A	STREET	Acid	<del>,</del>	no adjuvant therapy S or T	Chemotherapy S or T	Immunotherapy S or T	
20	R				<del> </del>		3013		3011	
29 30	Н	~	Y		ļ		R HH	R	R HY	
		3			<del> </del>	ļ		Ω		
31					ļ				ļ	
32	Υ				ļ		Ϋ́	Y	Y	
33	N				ļ		Ŋ	N	N	
34	R						R	R	R	
35	E						E	E	E E	
36	E			L	<u> </u>		E	E	E	
37	D	I	Y				ж ш ж үү	R E E DY	()	DQ26 ST is same as DQ37I
38	A R	V					A or V	A or V	A or V	
38 39	R						R	R	R	
40	F						F	F	F	
41	D						D	D	D	
42 43	S	1112110011					S	S	S	
43	D					11	D	D	D	
44	V				T	1	\$ D V	D V	S D V	
45	Ě	G	<b></b>		<b>†</b>		E or G	EG	E or G	
46	Ē	Ÿ			<b> </b>		()	()	()	DQ28 ST is same as
47	F	Ϋ́				}	()	()	()	DQ46VE DQ26 ST is same as
		,								DQ47FY
48	R		ļ	L	L		R	R	R	
49	Α						A	A	A	
50	V						V	V	V	
51	T						Ţ	Υ	T	
52	L	þ					()	()	0	DQ26 ST is same as DQ52PL
53	L.	Q					LL	L or Q	LorQ	
54	G						G	G	G	
55	i.	D.	R				PorR	P or R	PorR	DQ26 ST is same as DQ55L
56	L	þ					LP	pp	Lorp	
57 58	Α	۵	S	V			()	()	AA A	
58	A						A	A	A	
59	E Y						E Y	E	E Y	
60	Y						Y	Y	Y	
61	W				·		W	E Y W	W	
62	N				<b></b>		N	N	N	
63	S					1	Š	5	S	
64	Q				<b></b>	1			Q	
65	ĸ					····	Q K	Q K	ĸ	
66	Ď	Ē	<b></b>		<b>†</b>	<del>  </del>	DE	DE	EE	
67	ī	V	-			1-1	1V	IV	T VV	
68	Ĺ				<del> </del>	1-1	i.	Ĺ	Ĺ	
69	Ē			ļ	1	1-1	Ě	Ĕ		
70		-G	<u> </u>		<b>†</b>	<del>  </del>		<del>-</del>	E ()	
71	<b></b>		····		<del> </del>	<del>  </del>			<del></del>	
72	R	<u>D</u>	_K_	T	<b></b>	<del>  </del>	() R	Û R	AT R	
	***********		ļ		<b> </b>					
73	A.		<u> </u>	ļ	ļ	<del>  </del>	A	A	A	
74	A	E	S	ļ	ļ		ES	Q	ES .	
75	L_	V		ļ	ļ		ĽV	<u>Q</u>	<u>Q</u>	
76	D			ļ	ļ	ļļ	<u>D</u>	<u>D</u> ()	D RT	
77	R	T	ļ	L	ļ		0	0	RT	
78	V			L		1	V	V	V	
79	C	L	L	L	<u> </u>		C R	C R	C	
80	R			L			R	R	R	
81	Н						Н	Н	H	
82	N	L					N	N	N	
83	Y						Ÿ	Y	Y	
84	E	Q		·	T		QQ	()	QQ	
85	L	V		······	T		LL	Ó	()	
86	A	E	G	·····	T		0	Ú	EG	
***************************************				4	*******	***************************************				4

Fig. 92

Position		Di	verse A	mino A	old		no adjuvant therapy	Chemotherapy	Immunotherapy	
87	F	L	Y				FY	()	LY	·
88	Ŕ		<b></b>				R	() R	R	<del> </del>
89	G	Ŧ					ŤŤ	()	0	·
90	<u> </u>	Ť					ή÷	X	Ö	
91	<del>i</del>						Ĺ			
92	<u>`</u>						ā	Q	Q	
93	R						Ŕ	Ŕ	R R	·
94	R						R	Ŕ	R	-
95	<del></del>						V	······································	<del>-</del>	
96	E						E	E	E	
97	<u></u>						5	<del>-</del>	<del></del>	
98	<del></del>						<del>-</del>	T	T	
		<b></b>	ļ	ļ	ļ			<del></del>	<del>-</del>	·
99	Ā		<b></b>	ļ	ļ		Ž.	Ť	Ť	ļ
100	Ţ				ļ		Ţ		·····	-
101		ļ					1	1		
102	S	ļ			ļ		\$	\$	\$	ļ
103	p						b	P	p	-
104	SS						\$	\$	\$	ļ
105	R						R	R	R	
106	Ţ						Ţ	Ţ	1	ļ
107	E						£	E	<u> </u>	
108	Α						A	A	A	
109	L						L	L	ب	
110	N						N	N	2	
311	H						H	H	I	
112	Н						H	Н	Н	
113	N						N	N	N	
114	L						L.	Ļ	L	
115	L						L	Ļ	Ļ	
116	1	V							17	
117	C						<u>;</u>	<u>()</u>	C	
118	S						S	S	5	
119	V						V	V	V	
120	T						T	T	Ţ	1
121	D						Đ	D	D	
122	F						F	۴	F	
123	Ÿ						Y	Y	Y	
124	p						P	P	þ	-
125	A	G	S				GS	()	()	
126	H	ã			<b> </b>		()	HΩ	Ŏ	†
127	<del>``</del>	·····			<b></b>		······	}	Υ	†
128	ĸ						K	K	K	<u> </u>
129	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~				<b></b>		Ÿ	Ÿ	Ÿ	†*************************************
130	Q	R	·		<b>†</b>		()	RR	QR	†
131	W	<del>                                     </del>			<b></b>		W	W	W	<del> </del>
132		<b> </b>	<b></b>	<b></b>	<del> </del>		£			<b>†</b>
133	F R				<del> </del>		Ŕ	F R	F R	+
134	N	<b></b>		<del> </del>	<del> </del>		N	N	N	<del> </del>
135	ď	<del> </del>			<del> </del>		D C	Ď	D	<del></del>
136	<u>o</u>	<b></b>		<b></b>	<b></b>		—— <u>~</u>		Q	·
137	E E	<b></b>					Q E	Q E	8	<del></del>
138		<b></b>			<del> </del>		<u> </u>	E-	<u> </u>	·
138 139	E T	<b></b>		<b></b>	<b></b>		E T	E T	E T	<del> </del>
		T		<b></b>			TT			<del> </del>
140	A	<u> </u>						ğ	Q	<del> </del>
141	G	ļ			ļ		G	Ğ.	G	-
142	V						٧	V	V <sub>j</sub>	
143	<u>v</u>	ļ			ļ		V	V	<b>∨</b>	ļ
144	S				ļ		\$	S	S	<b></b>
145	T	}			1	1	τ	Ţ	T	

Fig. 93

Position		Di	verse A	mino A	old		no adjuvant theraov	Chemotherapy	lmmunotherapy	
146	p						therapy P	P	ρ	
147	L.						3	Ĺ		
148	1						1	Ĭ		-
	<del>-</del>		ļ	ļ			Ť	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	***************************************	
149						ļ		Ţ	Ţ	
150	N						N	N	N	
151	G						G	G	G	
152	D						Ð	D	D	
153	W						W	W	W	
154	Ŧ						Ť	7		
155	W T F						Ť F	Ť	T F	
156	Q						à	à	a .	
									~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	
157			ļ				1	1	1	
158	L				L	<b></b>	L	L	L	
159	V						V	V	V	
160	M						M	M	Z	
161	L		<u> </u>	[	I		L	Ĺ	L	
162	Ē		<b></b>	·	<b></b>	1	Ē	Ē	Ë	
163	M						M	M	M	+
	T						T	T T	T T	+
164							p	P		+
165	p		ļ				******	***************************************	p	
166	Q		L				Q	Q	Q	
167	H	R					()	HH	RR	
168	G						G	G	G	
169	D						Đ	D	D	-
170	v						V	V	V	·
171	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~						~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	Ÿ	Y	
				<u> </u>						
172	T C						T C	Ţ	Ť	
173							C	C	C	
174	}-						H	H	Ŧ	
175	V						V	V	V	
176	E						€	E	£	
177	Н		<b>†</b>	······		***************************************	Н	Н	H	·
178	P						P	P	P	
179	S						S	Ş	5	
180	L						L	L	L	
181	Q						Q	Q	Q	
182	2 0	S					NN	() P	<u> </u>	
183	P						p	P	p	
184							1	}	}	
185	·	7					ìı	ŤŤ	()	-
186	Ÿ	····					Ÿ	Ÿ	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	+
***************************************									***************************************	-
187	E			ļ	<b></b>	<b></b>	E	E	E	
188	W	ļ					W	W	W	
189	R	-					R	R	R	
190	Α		1			1	Α	A	Á	
191			<u> </u>					<del></del>	<del>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~</del>	1
192	C) S)		<b>†</b>			<b>†</b>	O S	Q S	Q S	
193	E						E.	E E	3 W	
	<u>.</u>		<b> </b>	ļ				#.	<u> </u>	
194	S		ļ				S A	S	S A	
195	A				ļ	<b></b>	A	A Q	A	
196	Q						Q	Q	Q	
197	N	S					SS	NS	()	
198	K		T				K	K	<u> </u>	
199	M		<b>1</b>	<b>!</b>		1	М	M	M	1
200	L		<b>†</b>	<del> </del>			~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~		+
	<u></u>		<b></b>	<del> </del>	ļ	<b></b>	ŗ	ř	ř	
201	S G						S G	S G	\$ G	
202							G	G	G	
203	1	٧					()	0	0	
204	G						G	G	G	
		~~~~~								

Fig. 94

Position		Di	verse A	mino A	old		no adjuvant therapy	Chemotherapy	lmmunotherapy	
205	G F						G F	G F	G	
206	F						F	£	F	
207	V						V	V	V	
208	L						L	L.	L.	
209	G						G	G	G	
210	L						L	Ł.	L.	
211	1						1	1		
212	F						٤	F	F	
213	L						Ĺ	L	L	
214	G						G	G	G	
215	L.						Į.	l.	l,	
216	G						G	G	G	
217	L						L	L	L	
218	I						1	<b> </b>	1	
219	<u>-</u>						1	1	1	
220	Н	R					HH	()	()	
221	H	Q					HH	()	()	
222	R						R	Ř	Ř	
223	S						S	\$	S	
224	Q	R					()	()	QR	
225	K						K	K	K	
226	G						G	G	G	
227	P						P	P	Ρ	
228	Q						Q	Q	Q	
229	G						G	G	G	
230	P						P	P	Ρ	
231	P						p	P	P	
232	P						p	p	Р	
233	Α						Α	A	A	
234	G						G	G	G	
235	L						Ĺ	L	L	
236	L.						Į.	L.	L.	
237	H						Н	H	Н	
	<del>-</del>	2	L	A	1	1			L	

Fig. 95

Position	•••••	Di	verse A	mino Ad	id	•••••	no adjuvant therapy	Chemotherapy	Immunotherapy	
_29	M						M	М	M	T
28	У						٧	V	V	
27	C		-				C	¢	C	
26	L						L	L	L	
25	K	R					RR	RR	RR	
24	F	Ĺ					ForL	ForL	ForL	
23	P						D,	P	P	
_22	G						G	G	G	
_21	G		***************************************	~~~~~		***************************************	G	G	G	
_20	Š				***************************************	***********	Š	S	5	
_19	S						S	S C	C	
_18	M						M	M	M	
17	A	T					AA	AA	_ AA _	
16	A	Ý					Ŵ	Ŵ	A or V	
15	- C	······					L,	Ĺ	L L	
14	Ť						Ť	Ť	Ť	
_13	<del></del>							- v	<del>'</del>	
_13	<u>`</u>						Ť	Ť	<u>v</u>	<del> </del>
		ļ						······		<b></b>
11	L	<b></b>					L	L	1.4	ļ
_10	M						M	M	M	
9	У						V	V	V	
8	Ļ						Ļ	<u> </u>	<u>L</u>	
_8	S						တ	8	S	
6	S						S	\$	S	
_5	Þ						Þ	р	P	
_4	L						Ĺ	L	L	
_3	Α						А	A	A	
_2	L.						į.	L	L	
_1	A	S					A or S	AorS	AA	
1	G						G	G	G	
2	D						D	D	D	
3	T						Ĭ	Ţ	T	
4	Q	R					QorR	QorR	QR	
5	Q P						P	P	р	
6	R						R	R	R	
7	R F						R F	F	F	
8							L	L	L	<b></b>
9	L E	K	W				()	WW	KW	<b>†</b>
10	Ē	à	Ÿ				₹	()	()	<del> </del>
11	D	Ğ	Ĺ	P	S		DS	Ö	DP	<b>†</b>
12	<u>×</u>	<del></del>		·		······	KorT	KorT	K or T	<b>†</b>
13	K F	T G	н	R	S	Y	GH	()	FS	<del> </del>
14	Ė	K	,,,	·····		·····	EorK	E or K	E or K	<del> </del>
15	~~~						~ ~ ~	- <del>2</del> 2, 3	~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~	<del> </del>
15 16	C H	Q	Y				C	C YY	C A	
17	<u></u>		······				<u>()</u>	P**	<u>()</u>	
18	<del></del>	ļ					F	F	F	
19	N	<b></b>					N	ļ	N N	
18	<del></del>						14	N G	G G	
20	G T	ļ			ļ		G T	<u> </u>	T	<b></b>
21	<u> </u>							Ţ		ļ
22	E	L					E	E	E	
23	R						R	R	R	
24	V						٧	У	V	
25	Q	R					QorR	QorR	QorR	
26	F	L	Υ		L		FL	()	FL	ļ
27	L						L () R	L	L	
28	D	E	н				0	L ()	()	
29 30	R						R	Ř	R	
30	C	G	Н	L	R	Y	()	()	()	

Fig. 96

Position	•••••	Di	verse A	mino A	sid		no adjuvant therapy	Chemotherapy	Immunotherapy	
31	F	T 1	V	Ī	1	1	Forl	Forl	FI	
32	H	Ÿ	×				HH	()	()	
33	H	N		·	<del> </del>		()	Ö	HH	
34	Q.	,,,			1		à	Q	ä	
35	E			·	<del> </del>		€	<u> </u>	E	
36	Ē				<del> </del>		Ë	Ë	Ë	
37	<del></del>	Ĺ	N	s	Y		()	LŸ	NS	
38	Ä	1	Ÿ	<del> </del>	<del> </del>		()	()	T VV	
39	<del></del>		······		<del> </del>		Ř	Ř	Ř	***************************************
40	<del></del>	Ϋ́			ļ		ForY	ForY	FF	***************************************
		······		<del> </del>	<del> </del>				Ď	
41 42	D S				<del> </del>		D S	D S	S	
43							D	D	D 0	
44	D V						V	v v	V	
45	G			ļ	<del> </del>					
	- 5				<del> </del>		G	G E	G	
46 47	шш	Ÿ		ļ	ļ		E		E	
4/		Y					ForY	ForY	ForY	
48 49	R	ļ		ļ	<b></b>		R	Ŗ	R	
49 50	<u>A</u>			ļ	ļ		A V	A V	÷	
				ļ						
51	Ť						Ť	Ť	Ţ	
52	E						E	E	Æ	
53	۳.				ļ		Ł	L	L	
54	Ö				ļ		G	G	G	
55	R						R	R	Ř	
56	D.						p	Ω	P	
57	Α	D	S	V			AV	ΑV	AV	
58	Α	Ε					A or E	A or E	A or E	
59	E						E	E	E	
60	H	S	Y		1		()	ΥΥ	HS	
61	W						W	W	W	
62	N						N	N	N	
63	S						S	S	S	
64	Q						Q	Q	Q	
65	K						К	K	К	
66	D F						Đ	D	Đ	
67	Ę	1	L				FF	FI	FL.	
68	L						L	L.	Ĺ.	
69	E						E	E	E	
70	D	Q	R				()	DD	()	
70 71	D A	Q E	R K	श			A	A	Ä	
72 73	R A				1		A R	R	A R	
73	Α	G					AA	A or G	A or G	
74	Α	ε	Ĺ	Q	R		0	L	AE	
74 75	A V						ν	V	V	
76	ď	T		T	1	T	D	D	Q	
77	D N	T		1	1		NorT	N or T	NorT	
78	V	Ÿ		1	1	1	VV	V or Y	VY	
79	C			1	1		С	C	C	
80	R	·		Ī	1		R	C R	G R	
81	H	<b></b>			1	<b></b>	H	H	H	
82	N	<b> </b>		<b> </b>	1		N	N N	N	
83	Ŷ				1		Ÿ	Ÿ	Ŷ	
84	Ġ			İ	1		Ġ	Ġ	Ġ	
85	Ā	V	<b></b>	<u> </u>	1		A or V	A or V	vv	
86				<b></b>	<del> </del>		VV	GV GV	ĞĞ	•••••
87	<u></u>	ļ <u>v</u>		<del> </del>	<del> </del>					
88	ши	<b></b>	<b></b>	ļ	<del> </del>		8 S F	E S	E S F	
89	<u>-</u> -	<b></b>	<b></b>	ļ	<del> </del>	<b></b>		<u> </u>		
59	5	i	į.	į.	1	1	t F	, ·	1 1	i

Fig. 97

90	Position	•••••	Di	verse A	mino A	oid	no adjuvant therapy	Chemotherapy	lmmunotherapy	
91	90	T				T T	1	Ť	Ť	T
92  Q  Q  Q  Q  Q  Q  Q  Q  Q  Q  Q  Q  Q	91						V		V	
93	92	Q					Q	Q	Q	
94		R						R		
956		R						R	R	
96								V	V	
97			Н	O	Y		£	()	4	
98    E									<u> </u>	·····
99				······						***************************************
100										
101		<u>-</u>						T	Ť	<del> </del>
102		·····						······································	······································	
103		<del>-</del>					· · · · · ·	V	······································	<del> </del>
104		- 6								
105			<u> </u>							<del> </del>
107			9							10
107		K					<u> </u>	<u>K</u>	<u>K</u>	ļ
109								<u> </u>		ļ
109		Q				ļ	<u> </u>	<u>Q</u>	<u> </u>	<b></b>
1110					<b></b>	ļ				ļ
111										
112										
113	111	H								
114							H	H	H	
115	113	N					N	N	N	
116	114	L					L	L	L.	
116	115						Ĺ	L	L	
117							V	V	ν	
118   S		С					С	С	С	<u> </u>
119				·					S	<b>†</b>
120							V	V	V	
121   F			8							<u> </u>
122   G		<del>- È</del>							E	·
124										<del> </del>
124		<del>-</del>						<u>-</u>	<del>-</del>	<del> </del>
125   G			·							
126   S										<del> </del>
127		<u>\</u>							<u>`</u>	
128   E				ļ						ļ
129										
130   R		<u>E</u>								ļ
133		Λ					<u> </u>		Λ	
133	130	<u> </u>				<b> </b>	K	K	<u> </u>	
133		W					W	W	W	
134	132			L		L			F	
135         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G         G			R					LorR	RR	
135   G	134	N						N	N	
137         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E		G					G	G	G	
137         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E         E		Q					Q	Q	Q	
138   E		E					E	Ε	E	
140     A     T     ()     TT     ()       141     G     G     G     G       142     M     V     VV     MorV     VV       143     V     V     V     V     V       144     S     S     S     S       145     T     T     T     T       146     G     G     G     G	138	E					Ε	E	E	
140     A     T     ()     TT     ()       141     G     G     G     G       142     M     V     VV     MorV     VV       143     V     V     V     V     V       144     S     S     S     S       145     T     T     T     T       146     G     G     G     G							K	ĸ	К	
141         G         G         G         G           142         M         V         VV         Mor V         VV           143         V         V         V         V         V           144         S         S         S         S         S           145         T         T         T         T         T         T           146         G         G         G         G         G         G         G			T					TT	()	1
142     M     V     Mor V     VV       143     V     V     V     V       144     S     S     S     S       145     T     T     T     T       146     G     G     G     G									Ğ	
143         V         V         V         V           144         S         S         S         S           145         T         T         T         T           146         G         G         G         G			V					MorV		
144         S         S         S         S           145         T         T         T         T         T           146         G         G         G         G         G			·	<b></b>						
145 T T T T T T T T 146 G G G G			·	<b></b>						1
146 G G G G			ļ			<del> </del>			<del>-</del>	<del> </del>
			·····	<b></b>		<del>  </del>		,	<del> </del>	<del> </del>
			ļ			<b>!</b>				<del> </del>
148 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		L I	ļ			<b></b>			L L	<del> </del>

Fig. 98

Position		Di	verse A	mino A	old		no adjuvant therapy	Chemotherapy	Immunotherapy	
149		Q	r	r	1		H or Q	HH	НН	
150	<del>\(\)</del>						N	N	N N	
151	G						G	Ğ	G	
152	D			·			D	0	a	
153	<u>W</u>						W	W	w	
154	7						Ť	T	7	
155	<del>;</del>						F	F	F	
156	<u>`</u>						à	<del>`</del>	ä	
157	<del></del>						Ŧ	<del>-</del>	T	
158	<u>L</u>						~~~~~~~~~~~	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	***************************************	
	····						V L	V V	L V	
159	V M								<del> </del>	
160							M	M	M	
161	<u> </u>						<u>L</u>	<u>L</u>	<u>Ļ</u>	
162	Ē			ļ			E.	E	E	
163	Ţ			<u> </u>			Ť	Ţ	_ T	
164	F						<u> </u>	<u>Q</u>	<u> </u>	
165	P						Р	P	P	
166	Q	R					QorR	QorR	RR	
167	S G						S	S	Ş	
168	<u>G</u>			ļ			G	G	G	
169	E						€	E	E	
170	У						٧	V	У	
171	Y						Y	Y	Y	
172	T						Ţ	T	Ţ	
173	C						C	Ç	C	
174	Q						Q	Q	Q	
175	V						V	V	V	
176	E						٤	E	E	
177	H				1		Н	H	Н	
178	P						þ	p	ρ	
179	S						\$	Ş	S	
180	L	V					LorV	L or V	L or V	
161	M	T					()	0	()	
182							Ŝ	Š	Š	
183	S P						Р	P	P	
184								Ļ	L	
185	<u>_</u>						Ť	Ť	T	
186	V						V	V	V	
187	Ē						Ē	Ē	E	
188	<u></u>		·	·····	1		W	W	W	
189	R	S	1		1		RR	Rors	RorS	
190	A				1		A		A	
191	A R		<b></b>				A R	A R	A R	
192	\$		<b></b>				S	s s	Š	
193	Ě						Ě	E	E	
194			<b>!</b>	·	1				<u>-</u> -	
195	S A		<b></b>	<b>!</b>	<b>†</b>		S A	S A	S A Q	
196	<del></del> Q		<b></b>	·····	<del> </del>		Q	Q	<del></del>	<u> </u>
197	<del></del> S				<b>†</b>		S	<u></u> S	<u> </u>	
198	<del></del>		·····	<del> </del>	<del> </del>		ĸ	ĸ	S K	
199	M						M	M	M	
200	L						L L	L	L	
			ļ					8		
201 202	S G						8 G	G G	S G	
	V						V	<u>U</u> V	V	
203			ļ	ļ				<u>~</u>		
204	<u> </u>			ļ			G	G	G	
205	G F		ļ	ļ	ļ		G F	G F	G F	
206									F	
207	V	1	l .	E	1	1	V	V	V	1

Fig. 99

Position	•••••	Di	verse Ar	nino Acid	no adjuvant therapy	Chemotherapy	lmmunotherapy	
208	لد				Ł.	L.	L	
209	G				G	G	G	
210	ئــ				į.	L	L.	
211	L				Ĺ	L	Ĺ	
212	ų.				F	F	F	
213 214	لد				L	L	L	
214	G				G	G	G	
215	A				A	A	Α	
216	G				G	G	G	
217	L				L	L	L	
218	Ę.				F	٤	F	
219	Į.				<b>{</b>	}	<b> </b>	
220	Y				Y	À.	Y	
221	۴				F	ŧ	۴	
222	R				R	R	R	
223	N				N	N	N	
224	Q				Q	Q	Q	
225	K				K	К	к	
226	G				G	G	Ğ	
227	H				Н	}-}	H	
228	S				S	\$	\$	
229	G				G	G	G	
230	لد				Ĺ	L	L	
231	p.	Q			PorQ	P or Q	QQ	
232	<b>1</b>				P	þ	Þ	
233	R	Ŧ			RorT	RorT	RorT	
234	G				G	G	G	
235	F				F	F	F	
236	L				Ĺ	L	L	
237	S				S	S	S	

Fig. 100

Position		Di	verse A	mino A	zid	***************************************	Amino Acid Configuration to Inhibit Metastases
_29	M						M
_28	M			······		<b></b>	M
_27	V						V
_26	Ľ	<b></b>		·····			i i
25	ā						
	<u> </u>						Q
_24	V						V.
_23	s						S
22	Α						A
_21	Α						A
_20	P						P
19	R						R
18	T						Ť
_17	Ÿ						V
16	À						<u> </u>
							A
15	L T						E T
14							
_13	Α						A
12	L						Ł.
_11	L				I	1	Ł.
10	M			·	·	1	M
9	V					·····	V
_8_	Ľ.	·····					i i
7							
	L					ļ	<u>.</u>
6	T						T
5	S						\$
4	V						V
3 2 1	V Q						ν α
2	Q						Q
1	G						G
1	R						R
2	Ä						· · · · · · · · · · · · · · · · · · ·
<u>_</u>	<del></del>					······	<u>A</u>
3							
4	P						P
5	Æ						E
6	N						N
7	Y						Y
8	L	V					()
9	F	Н	Ÿ				()
10	Q					<del> </del>	ä
11							
	G R	<u>L</u>				<del> </del>	<u>Ų</u>
12		ļ		ļ			
13	Q E						Q
14	E						© E C
15	C						C
16	Y						Y
17						<u> </u>	
18	A						A F
19	***************************************	·····					
	N G						17
20	<u></u>					ļ	N G T
21	Ţ					<b></b>	I
22	Q			L			Ω
23	R						₹
24	£						<b>F</b>
25	L						L .
26	Ē						<u> </u>
27	R						27
27							R Y
28	Y				ļ		
29					ļ	ļ	
30	Y			<u> </u>		1	Y

Fig. 101

Position		Di	verse A	mino Ac	id	 Amino Acid Configuration to Inhibit Metastases
31	N			·		 N
32	R	······		····		 Ŕ
33	Ē			·		 Ē
				<del> </del>		
34	E					 Ę
35 36	ļ	L.	Υ	<b></b>		 Q
36	A R	٧				 <u>Q</u>
37	R					 R
38	F					F
39	D					D
40	S					 S
41	Ď					 Ō
42						 <u> </u>
43	> G #					 7 G E F
43	<u> </u>					 5
44	<u>E</u>					 <u></u>
45						 F
46	R					 R
47	Α					А
48	V					V
49	T					 Ť
50	É		·			 Ė
51	<u> </u>	<b></b>	·····	<del> </del>		
52	Ğ			<b></b>		 E G
						 G
53	R					 R
54	þ					 P
55	Α	Ð	E			 AA .
56	A	шш				()
57	D	E				
58	D Y					 <u> </u>
59	Ŵ			·		 Ŵ
60	N					 N N
61	· · · · · ·					 \$
	S Q			ļ		 3
62	- Q	•••••				 Q
63	K					 K
64	D					 0
65	۴	}	L			()
66						
	L	· · · · · ·		1	1	
	L E					 £
67						£
67 68	E					E E
67 68 69	E E	K				E E
67 68 69 70	E E E					£
67 68 69 70 71	E E E					£
67 68 69 70 71 72	E E E					£
67 68 69 70 71 72 73	E E R A > P					L E C Q R A V
67 68 69 70 71 72 73 74	E E R A V P					L E E () R A V P
67 68 69 70 71 72 73 74	E E R A V P					L E E () R A V P
67 68 69 70 71 72 73 74 75	# # # # # # # # # # # # # # # # # # #	K				L E E () R A V P D R
67 68 69 70 71 72 73 74 74 75 76	# # # # # # # # # # # # # # # # # # #		V			L E E () R A V P D R
67 68 69 70 71 72 73 74 75 76	######################################	K				L E E O) R A V P D R D R
67 68 69 70 71 72 73 74 75 76 77	20 - 0 - 0 - 0 - 0 R	K				L E E O) R A V P D R D R
67 68 69 70 71 72 73 74 75 76 77 78	T 20 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	K				E E O R A V P P O R O C R H
67 68 69 70 71 72 73 74 75 76 77 78 79		K				L E E C C R C C R H N
67 68 69 70 71 72 73 74 75 76 77 78 79 80 81		K				L E E C C R C R C R R C C R R R C C R R R C C R R R C C R R R C C R R R C C R R R C C R R R C C R R R C C R R R C C R R R C C R R R C C R R R R C C R R R R C C R R R R R R R R R R R R R R R R R R R R
67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82	m <2 x x 2 x 2 x x m m m	K				
67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82	m <2 x x 2 x 2 x x m m m	K				
67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83	~ m <ziixo -="" td="" u<<="" xo=""><td>K</td><td></td><td></td><td></td><td>L E E C C R C C R C C R C C R C C C R C C C R C C C C C C C C C C C C C C C C C C C C</td></ziixo>	K				L E E C C R C C R C C R C C R C C C R C C C R C C C C C C C C C C C C C C C C C C C C
67 68 69 70 71 72 73 73 74 75 76 77 78 79 80 81 81 82 83 84	O	۵ کے ا				L E E C C R R H N N Y E L C C C C C C C C C C C C C C C C C C
67 68 69 70 71 72 73 73 74 75 76 77 78 79 80 81 81 82 83 84 85	m	88 88				E E E C C C C C C C C C C C C C C C C C
67 68 69 70 71 72 73 74 74 75 76 77 78 79 80 81 82 83 84 84	У M C Г M ( Z I I M O – M C Ф < Р Ж M M M M	88 88				E E C C C C C C C C C C C C C C C C C C
67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87	X V m C I I N O U C V N m m m	۵ کے ا				E E C C C C C C C C C C C C C C C C C C
67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 84	У M C Г M ( Z I I M O – M C Ф < Р Ж M M M M	88 88				E E E C C C C C C C C C C C C C C C C C

Fig. 102

Position		D	iverse A	mino A	zíd	************	Amino Acid Configuration to Inhibit Metastases
90	Q R	1					
91	R					1	Q R
92	R		1			1	R
93	V		·				V
		<b></b>	<b></b>				
94	Ö				ļ		<u>Q</u>
95	P	ļ			ļ		р
96	K	R					0
97	V						V
98	N						N
99	V	······	·		<b>†</b>	<del></del>	V
100	ŝ		<b></b>	·····	<del> </del>	·····	Š
		ļ				ļ	P
101	S K				ļ	ļ	<u>r</u>
102	5						S K
103	K						К
104	K						K
105	G					1	G
106	P				<del> </del>	1	P
	<del></del>				ļ	<del> </del>	[
107	Ļ	ļ	ļ		ļ	<b>!</b>	<u>L</u>
108	Q				1	1	Q
109	Н	1					H
110	H					]	H
111	N	······	1		1	1	N
112	+	<b></b>	<b>†</b>		<del> </del>	<del> </del>	<u> </u>
	<u> </u>	ļ			ļ	<del> </del>	<u></u>
113	L	ļ	ļ		ļ		
114	V						V
115	C						C
116	H V						H
117	V						V
118	<del>                                     </del>				<b></b>	<del> </del>	Ť
		ļ			ļ	ļ	<del></del>
119	D	ļ					<u>D</u>
120	F				l		F
121						1	Y
122	P						P
123	G						G
124	Š	<b></b>			<del> </del>	1	S
	l i						
125		ļ	ļ			<u> </u>	1
126	Q V					1	Q
127						i	V
128	R						R
129	W						W
130	F	·			·	·	F
131	<del>  </del>	<b></b>	<b>†</b>	·····	<del> </del>	<del> </del>	
	L N					}	<u> </u>
132					ļ	ļ	N
133	G						G
134	Q				1	1	Q
135	E					1	E
136	E	<b>†</b>				<b>!</b>	<u> </u>
	2 00		<del> </del>		<b></b>	<del> </del>	
137							I .
138	Α	<b></b>	ļ			<b></b>	A
139	G				1	1	G V
140	V						V
141	V	·	1		1	1	V
142	S	<b>!</b>		·····	<del> </del>	<del> </del>	Š
						<del> </del>	
143	Ţ					1	T
144	N					1	N
145	L I						L.
146		1	T		1	1	1
147	Ŕ	<b></b>	†	·····	<b>†</b>	<del> </del>	Ř
		<del> </del>	<b></b>	<b></b>	<del> </del>	<del> </del>	N N
148	N	L	L	L	1	1	I N

Fig. 103

Position		Di	verse Amino A	cid	••••••	Amino Acid Configuration to Inhibit Metastases
149	G			1	1	G
150	D			1	<del> </del>	Ď
151	W			1	<del> </del>	W
152	Ť			1	1	Ť
153	Ė			1	<del> </del>	<del>.</del> F
154						à
155	Q					<u> </u>
156			<b></b>	<del></del>		
	V V					L. V
157				<del></del>	<del> </del>	
158	M			<u>_</u>		M
159	L				ļ	<u>L</u>
160	E M					E M T
161	M					<i></i> ₩
162	T					T
163	P			1		P
164	Q					Q
165	Q					Q
166	G					G
167	D					D
168	V			1	1	V
169	Υ			1	1	Ÿ
170		Ŧ		1	1	()
171	Ç			1		č
172	Q			1	1	Q
173	V			1	<del> </del>	Ž
174	E			+	<del> </del>	¥
175			<b></b>	-		ü
176	H T					H T
				-	ļ	
177	S				ļ	S
178	l.	M			ļ	<u>Q</u>
179	D S					<u>D</u>
180	<u></u>			-		S
181	P			-		P
182	У			1		V
183	T					Ť
184	V					V
185	E			1	1	E
186	W					W
187	К					К
188	A					A
189	Q			1	1	Q
190	Q S D			T	1	\$ D
191	D					D
192	ŝ					\$
193	Ā			1	1	Ă
194	₽,			1	1	R
195	R S		<b></b>		<b>!</b>	\$
			<b> </b>	-	<del> </del>	· · · · · · · · · · · · · · · · · · ·
196	K T		ļ	-		K T
197			<b></b>	<del></del>	ļ	
198	L T		ļ	-	<b> </b>	<u> </u>
199			ļ	-	ļ	
200	G				ļ	G
201	Α					A
202	G					G
203	G					G
204	<b>#</b>			1	1	F V
205	V					V
206	L			1	1	L.
207	G			1	1	Ğ
		·····	·····	<del>~~~~~~</del>	***************************************	<b></b>

Fig. 104

Position		Diverse Amino Acid	\$ Amino Acid Configuration to Inhibit Metastases
208	L		ξ.
209	1		ļ
210	1		į.
211	C		C
212	G		G
213	٧		V
214	G		G
215	1		ŧ
216	۶		۶
217	M		M
218	H		Н
219	R		R
220	R		R
221	S		S
222	К		K
223	К		К
224	V		V
225	Q		Q
226	R		R
227	G		G
228	S		\$
229	Α		A

Fig. 105

26 L 25 R 24 I	9		Amino Acid Configuration to Inhibit Metastases M S W
31 S 30 W 29 K 28 K 27 A 26 L 25 R 24 I	S		S W
30 W 29 K 28 K 27 A 26 L 25 R 24 I	S		W
28 K 27 A 26 L 25 R 24 I	S		1.e
28 K 27 A 26 L 25 R 24 I	S	***************************************	
27 A 26 L 25 R 24 I	S		<u>К</u> К
26 L 25 R 24 I			0
_25 R			<u> </u>
24 1			R
_23 P			P
-22 G			G
22 G 21 D	G		
			Ω
20 L 19 R			L R
	·		
	V		0
_17 A			A T
_16 T			T
_15 V			V
_14 T			T
13 L 12 M			l.
_12 M			M
_11 L			L.
	S		()
.9 1	M		()
9 1 8 L 7 S 6 S 5 L			į.
7 S			<u>L</u> 5
7 S 6 S	T		()
_5 L	P S		0
	v I		Ŏ
			<u> </u>
3 A 2 E			A E
1 G 1 R			<u> </u>
1 R 2 D 3 P			<u>R</u>
2 D 3 P	S		ļ
<del>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~</del>	5		O P
4 P			P
5 E 6 D 7 F			E
6 D 7 F			D F V
7 F			F
8 V 9 F			V
9 F	L Y		0
10 Q			Q
11 F			F
12 K			K
	G		()
	M		List
15 Č			Č
16 Y			Ť Ž
17 F			F
18 T			Ť
19 N			N N
20 G			G
- 40 G			
21 T			<u> </u>
22 E			E
23 L 24 V	R		()
24 V			V
25 R			R
26 G	L Y		()
27 V			V

Fig. 106

28 29 30		D	verse A	mino A	cid	Amino Acid Configuration to Inhibit Metastases
30	S	T				<u>0</u> 8
30	R					Ŕ
~~~~~	H	5	Y			()
31	1 1		1			
32	Ŷ		·····			Y
33	N					N
34	R				†	Ř
<del></del> 35	TE-		<del> </del>	<del> </del>	<del> </del>	
36	Ē		ļ	<del> </del>	<del> </del>	<u>E</u> <u>E</u>
			ļ		<b></b>	
37	D		Y	<b>ļ</b>		0
38	Α	V	<b></b>			Ω R F
39	R F				l	R
40	۶		1			F
41	D S					D S
42	S		1			S
43	D		1	1		0
44	V		<b>†</b>		† <u>†</u>	Ÿ
45	Ē	G	<del> </del>	1	<del> </del>	Ů.
		<del></del>	<del> </del>		<del> </del>	
46	<del> </del>	V Y	ļ	<del> </del>	<del> </del>	0
47	E F R	ř	}	ļ	ļ	<u>Q</u>
48						R
49	A					Α
50	V					V
51	7					T
52	L	P				()
53	L	Q	·			()
54	G		<del> </del>		1	Ğ
55	<del>l</del>	P	R		<del> </del>	Ö
		P	<del>  '``</del>	<del> </del>	<del>  </del>	
<u>56</u>	ļ <u>Ļ</u>	····	s	ļ	<del> </del>	<u> </u>
57	A	D	5	У	ļ	0
58	A			<b></b>		A
59	E					Ē
60	Y		1	1		Y W
61	W					W
62	N					N
63	S		1	1		S
64	Q		1	1		Q
65	<del>                                     </del>		<del> </del>	<b></b>	<del> </del>	ĸ
	K D	=	<del> </del>		<del> </del>	
66	}¥	E V	<b></b>	<b>]</b>	ļ	<u> </u>
67	1 1	<u>Y</u>	<b>}</b>	ļ	ļ	<u> </u>
68	L_L		<b></b>	ļ	ļ	<u>L</u>
69	E				<b></b>	E.
70	E	G	R		<u> </u>	()
71	Α	D	K	Ŧ		()
72	R					8
73	A					A
74	A	E	s	1	<del>  </del>	- i
75	<u> </u>	Ÿ	<del> </del>		<del> </del>	***************************************
( )	<u> </u>	Y	<del> </del>		<del> </del>	<u> </u>
76			<del> </del>	<del> </del>	<del> </del>	
76	R	T	ļ	<b>!</b>	<del>                                     </del>	RT
76 77	٧		<b> </b>	ļ		V
76 77 78						C
76 77 78 79	С			1		R
76 77 78 79 80	R			1		
76 77 78 79 80						H
76 77 78 79 80 81	R H					H
76 77 78 79 80 81 82	R H N					H N
76 77 78 79 80 81 82 83	R H N Y					Н N Y
76 77 78 79 80 81 82	R H N	ø>				H N

Fig. 107

Position				mino A	<u>pid</u>	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	Amino Acid Configuration to Inhibit Metastases
87	F	L	Y				LL
88	R						R
89	G	T					()
90	1	T					()
91	L						Ł.
92	Q						ä
93	Ř						Ř
	R		ļ	<del> </del>		ļ	Ŕ
94	~~~~						$\overline{V}$
95							V
96	E						E .
97	p						p
98	1						T V
99	V						V
100	T						T
101	1						
102	S						
103	P						S P
104	\$						S
		<b></b>	ļ	<del> </del>		ļ	
105	R T E						Ř
106			ļ	ļ		ļ	Ţ
107	Æ						Ĕ
108	A						A
109	L.						L.
110	N						N
111	Н						H
112	Н						H
113							N N
	N.						
114	<u> </u>						<u> </u>
115	<u>L</u>						Ł.
116	3	٧					IΛ
117	C			1			C S
118	S						S
119	٧						٧
120							V T
121	D						Ď
122	F						F
123	Ÿ						Ÿ
							P
124	p						
125	A H	G CI	S				AA ()
126	Н	Q					()
127	1						l l
128	K						K
129	V		·	1			V
130	Q	R					()
131	W		<b></b>	<b></b>		1	W
132	F						F F
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	R		<b></b>				
133							<u> </u>
134	N						<u>N</u>
135	D						Ō
136	Q						Q
137	£		1				£
138	E						E
139	Ť		<b></b>				Ť
140	À	Ŧ	<b> </b>			·	Ò
141	G						Ğ
							<u> </u>
142	V		ļ				<u>Y</u>
143	V						V
144	\$						\$ T
145	7	1		1	1		T

Fig. 108

Position		Di	verse A	mino Ac	oid	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	Amino Acid Configuration to Inhibit Metastases
146	P						F
147	L.						L
148	1						I
149	R						R
150	N						N N
151	G						G
152	Ď			~~~~~			Ď
153	W				<del> </del>	ļ	W
<del>,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,</del>	T						T T
154					ļ		į
155	Ę				ļ		F
156	Q						Q
157	1						Į L
158	L						<u>L</u>
159	V						V
160	M						M
161	L						Ł.
162	Ē						<b></b> €
163	M				<b>!</b>		M
164	T 189		····	·	<b> </b>	<b> </b>	T T
	p						7
165							P Q
166	Q	<u>_</u>					<u> </u>
167	H	R			ļ		<u> </u>
168	G						G
169	ם						D
170	V						У
171	Y T						Y T
172	Ŧ						T
173	Ç						С
174	H						Ħ
175	Ÿ				·····	······	Ÿ
176	Ě				·		Ě
177	<u></u>						اس ن
	H						Н Р ©
178	Þ						<u> </u>
179	S						<u> </u>
180	L						L
181	Q						Q
182	N	S					<u> </u>
183	p						ρ
184	1						
185	1	Ť					{}
186	Ÿ				1		<u> </u>
187	Ě	······			<b> </b>	······	Ė.
188	W						W
189							
	R				<del> </del>	<b> </b>	R A
190	<b></b>						~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
191	<u> </u>		ļ				Q
192	S						\$
193	E						E
194	s						S
195	Α						A
196	Q						Q
197	N	S			T	·	Ú.
198	ĸ					<b></b>	K
199	M		·		<b> </b>	<b> </b>	M
200							L L
					<b> </b>	<b> </b>	
201	S					ļ	S
202	G	L			ļ	ļ	G
203	1	V					ll
204	G					1	G

Fig. 109

Position		Ö	verse Amino Acid	Amino Acid Configuration to Inhibit Metastases
205	G			G
206	F			F
207	V			V
208	L			į,
209	G			G
210	Ł.			Ł.
211	1			<u> </u>
212	۶			F
213	L			<u>L</u>
214	G			G
215	L.			L.
216	G			G
217	L			L
218	1			
219	į			
220	H	R		()
221	Н	Q		()
222	R			R
223	S			S
224	Q	R		QR
225	ĸ			K
226	G			G
227	P			P
228	Q			Q
229	G			G
230	p			P
231	P			P
232	Þ			р
233	Α			A
234	G			G
235	L			1.
236	L			L.
237	Н			H

Fig. 110

Position		ni	verse A	mino A	niot .		Amino Acid Configuration to Inhibit Metastases
_29	M		V6136 V	THE CO AC	, , , , , , , , , , , , , , , , , , ,		
	V						M V
28	<u>v</u>						
_27	C						C
_26	L						<u> </u>
_25	K	R					() LL
_24	۶	Ł.					£L.
_23	P						P
_22	G		<b></b>		<b></b>		6
	G			·····			<u> </u>
_21	<u> </u>						<u>5</u>
_20	\$						\$
19 18	С						C M
_18	M						M
_17	Α	Т					()
16	A	V					Ò
_15	A L						<u> </u>
	<del></del>						<u>L</u>
_14	Ţ		ļ		ļ		Ť
_13	V						V
_12	Ŧ						Ţ
_11	L						L
10			<b></b>			1	M
	M V						
10 9			<b>}</b>				V
8	L						<u>L</u>
6	\$						\$
6	S						S
6 5	S P						P
4 3	<u>L</u>						<u> </u>
3	Α						A
_2	L.						Į.
_1	Α	S					Ò
1	G						G
2	Q						D
	<del>~~</del>						
3	Ţ						Ţ
4	Q	R					()
5	12		L				P
6	R						R
6 7	R F						R F
8							Į.
<del>-</del>	E E L	12"	587		<b></b>		
9 10	<u></u>	~	W Y L				0
10	E	u	ΥΥ				{}
11	D	G	L	Р	S	V	()
12	ĸ	к С Б					()
13	F	G	H	R	S	Y	()
14	E	K					Ö
	C						
15							Č .
16	Н	Q	Y				
17	F						F
18	٤		1				F
19	N						N
20	G						Ğ
					<b></b>		
21	Ť				ļ	ļ	<u>T</u>
22	E		<b></b>				€
23	R			L			R
24	٧		T				V
25	à	R	<b> </b>		<b></b>	·	Ö.
20	<del></del>		Y				<u>V</u>
26	F	L.	<u> </u>				Q
27	L						Į.
28	Q	E	Н				()
29	R			· · · · · · · · · · · · · · · · · · ·			R
30	C	G	H	Ĺ	R	Y	()
	·		1 7 1	1 -		1	1

Fig. 111

Position		Di	verse A	mino A	cid	Amino Acid Configuration to Inhibit Metastases
31	F		V	1	1	()
32	H	Ÿ	······		1	
33	H	N				0 0
34	<u> </u>					à
35	Q E					6
36	<u> </u>					E
37	m m	3	N	S	Y	Ö
38		<u></u>	<del></del>		ļ	X
39	A R	L	<del>-</del>			U R
	F	Υ				
40		Υ				<u>0</u>
41	0 0 0 2					D S D V G
42	5					<u> </u>
43	D					D
44						V
45	G					
46	£					E
47		Y				()
48	R					R
49	A V					A
50	٧					V
51	7					T
52	Æ					E
53	L					l.
54	G					G
55	R					Ř
56	P					P
57	À	n	\$	V		()
58	A	D E				Ö
59	E	5-				Ë
60	H	S	Υ Υ		·····	
61	W		ļ			U W
62	Ň					Ň
63	ø Ø					S
64	<u> </u>					Q
65	K					K
66	D					D
67	F		Ĺ			()
68	E D					<u> </u>
69	Æ					E
69 70	۵	Q	R			E 0
71	Α	Q E	R K	R		0
72	R					R
73	A	G				()
74	Α	E	L	Q	R	Ö
75	V			·		Ϋ́
76	D				1	D
77	Ň	T	h		1	()
78	TV T	Ÿ			<del> </del>	
79	è	·····	<b></b>		·	<u> </u>
80	R				-	R
81	H					H
			ļ		-	
82	N		ļ		ļ	N.
83	Y		ļ		ļ	Y
84	Ğ			ļ	ļ	G
85	Α	V	<b></b>			()
86	G	٧	<u> </u>			0
87	Æ					E
88	S					\$
89	۶			1		F

Fig. 112

etastases
<i></i>
***************************************
***************************************
,
***************************************
***************************************
***************************************
~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~

Fig. 113

Position			verse A	mino Ac	oid		Amino Acid Configuration to Inhibit Metastases
149	H	Q					()
150	N						N
151	G			***************************************			G
152	D			***************************************			Ō
153	W						W
154	W						Ť
155	F			***************************************			······································
156	à				·		Q
157	Ť						T T
<del>,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,</del>	<del>*************</del>						<del>~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~</del>
158	<u> </u>						<u> </u>
159	V						V
160	M						<u>Μ</u> ξ
161	L						
162	E T						E T
163	T						
164	F	У					()
165	P						P
166	Q	R					<u>()</u>
167	S		·				Š
168	Ğ						Ğ
169	G E V						Ē
170	<del></del>						
	Ÿ						Ÿ
171	+						
172							
173	C						<u>c</u>
174	Q						Q
175	V E						УУ
176	E						E
177	Н						H
178	P						P
179	\$						\$
180	L	٧					()
181	M	Ť					Ò
182							<u> </u>
183	S P						\$ P
184	Ĺ						i.
185	Ť						
	<del> </del>						<del></del>
186	V E						У
187	E						<u>V</u> E W
188	W						
189	R	S	L			L	()
190	A						A
191	R						R
192	S						\$
193	E						E
194	S						\$
195	Ä						Ă
196	à		<b> </b>				Q
197	s				·	<b> </b>	<u>``</u>
198	<u> </u>						<del></del>
	K		ļ				K M
199	M		ļ				M
200	L.		ļ		ļ		<u>k</u>
201	\$						S
202	G V						G V
203							
204	G						G
	<del>,</del>						
	] G		1 1		;	1 1	G
205 206	G F						G F

Fig. 114

Position		Di	verse Amino A	oid	Amino Acid Configuration to Inhibit Metastases
208	L				Ł.
209	G				G
210	L				Ł.
211	L				<u>t</u>
212	£				F
213	Ł.				į.
214	G				G
215	Α				A
216	G				G
217	L				<u>L</u>
218	F				F
219	1				
220	Y				Υ
221	Ę				F
222	R				Ŕ
223	N				N
224	Q				Q
225	ĸ				К
226	G				G
227	H				H
226	S				\$
229	G				G
230	L,				L.
231	þ	Q			()
232	Þ				P
233	R	Ŧ			()
234	G				G
235	۶				F
236	L				Ł.
237	S				S

Fig. 115

Position		D	iverse A	mino Ad	oid		Amino Acid Configuration With Less Tendency to Malignancy
_29	M	·	T	1	I		M
28	M		<del></del>		·	ł	M
	V V	<b></b>	ļ		ļ		V
<del></del>	<del></del>		ļ				
. 26							<u>L</u>
25	Q V						Q
24	V						V
_23	\$						S
_22	Α						A
_21	Α						A
20	A P		1				Р
19	R		·····				Я
18	T						<del>T</del>
17	v						ý
		ļ			ļ		
16	A	ļ			ļ		A
15	L.						<u>{</u>
_14	T	L	<u> </u>	1		1	Ţ
13	A			1			Á
_12	t.						L.
11	L.	1	1				L.
10	M	·	1	1	1	1	SM SM
9	~~ <del>````</del>	·	<b>†</b>			<b></b>	Ÿ
	L	<b></b>	<del> </del>		<b></b>		Ĺ
8 7		<b></b>	<b>}</b>	ļ	ļ	ļ	
	L		ļ				<u>.</u>
_6 _5	Ţ		ļ				
	S						S
_4	٧						V
3	V						V
_2	Q						Q
. 1	G			1			G
1	R		<b></b>				Ŗ
2	A		·				À
	<del></del>						
3	<del></del>	ļ	ļ		ļ		P
4			ļ	ļ	ļ		
5	E	<u> </u>	ļ		ļ		<b>E</b>
6	N						N
7	Y		1	1	İ		Y
8	Ł.	V					£L.
9	۴	Н	Y				
10	Q	······	<b>•</b>	1	·	1	Ğ
11	Ğ	L					ii.
12	R						
14			}				R
13	<u> </u>	ļ	<b>}</b>	ļ	ļ	ļ	2
14	Q E C	ļ	<b></b>	<b>!</b>	ļ	ļ	Q E C Y
15	<u> </u>	ļ	<u> </u>			1	<u>C</u>
16	Y						Y
17	A		1	1			A
18	F		I				A F
19	F	ļ	<b>†</b>	·			N
20		<b>!</b>	<b>!</b>	<b>!</b>	<b>!</b>	1	
21	G T	<del> </del>	<del> </del>	<del> </del>	<del> </del>	<b></b>	<u>ල</u> T
<u>&amp;_I</u>	<u> ;</u>	ļ	<b> </b>	<b></b>	<b> </b>	<b> </b>	ļ
22	<u>Q</u>	ļ	ļ	ļ	ļ	ļ	Q
23	Q & u.						Q R F
22 23 24	٤						F
25	L						Į.
26	E	<u> </u>	1	1	<u> </u>		E
27	E R	·	<b></b>		·	<b></b>	Ř
~~~	├	ļ	<b></b>		<b></b>	<b> </b>	· · · · · · · · · · · · · · · · · · ·
28	Y	ļ	ļ	ļ	ļ		Y.
29 30		ļ	<u> </u>	ļ	ļ	<u> </u>	
30	Y	1	1	1		1	Y

#### 116 / 129

Fig. 116

Fig. 11	16						
Position	1	Di	verse A	mino Ad	aid:		Amino Acid Configuration
							With Less Tendency to Malignancy
31	N						N
32	R						R
33	E						E
34	E		1				
35	F	Ĺ	Y	1			()
36	A	V					Ö
37	R						Ř
38	F	·				·····	F
39	Ġ	ļ					D
40	Š	·					5
41	D						D D
42	V						v v
	1 ~					-	
43	<u> </u>		ļ	ļ		<b>}</b>	<u>5</u>
44	G E F		ļ			ļ	G E F
45	F		ļ	ļ			F
46	R		<u> </u>	<b></b>		<b></b>	R
47	A						A
48	V T			1			
48 49 50	T			1			V T E L
50	Ε						E
51	L						Ł
52							G
53	G R P		1			1	R
54	p		·				P
55	A	D	ε			<del> </del>	()
56	À	F		·			Ö
57	D	E E	<del> </del>	<b>†</b>		<del> </del>	EÉ
58	Ϋ́	<del></del>	<b></b>	<del> </del>		<b></b>	Y
59	l ŵ	ļ	<b></b>	<del> </del>		<del> </del>	
							W N
60	N S		}			}	N
61	- 3	ļ	ļ	ļ		ļ	5
62	Q						Q
63	K		ļ			ļ	K
64	D F		<u> </u>			ļ	0
65	J. F.	1	Ļ	ļ			()
66	L						Ł
67	E		<u> </u>				Ē
68	Ε		L	1			Ē
69	E	K					()
70	R						R
71	A						A
72	l V		1	1			٧
73	P					1	P
74	D	1	1	1		1	Ð
75	D R		<b>†</b>			<b></b>	R
76	1	M	V			<del> </del>	i
77	<del>  </del>	···········	<del> </del>			<del> </del>	C
	1	<b> </b>	!	!		!	and the second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second second s
78	H-B-	ļ	ļ		ļ	ļ	F.3
79	H	ļ	ļ	<del> </del>		ļ	H
80	N		ļ	ļ		ļ	N
81	Y		ļ	ļ		ļ	<u> </u>
82	E					ļ	4
83	1 L						<u> </u>
84	D	G	1	1		1	GG
85	E	G					GG
88	Α	P	1			1	MM
86 87	M T	Ÿ					MM
88	T		T	·		I	Υ
89	L	<u> </u>	I	I			Ĺ,
***************************************		·	***********	***********	·	************	······································

Fig. 117

Position		Di	verse A	mino Ad	oid		Amino Acid Configuration With Less Tendency to Malignancy
90	Q					1	Q
91	R					·	R
92	R						R
93	V	<b></b>	······				V
94	Q	·					Q
95	P	<b></b>	·				P
96	К	R					()
97	V						V
98	N						N
99	V						V
100	S						\$
101	P						P
102	S						S
103	K						К
104	K						K
105	G						G
106	р						ρ
107	L						<u> </u>
108	Q						Q
109	Н						H
110	H						H
111	N						N
112	L						Ł
113	L						Ł
114	V						V
115	С						C
116	Н						H
117	V						V
118	Τ						Ť
119	D						D
120	F						F Y
121	Y						<u>Y</u>
122	P	ļ					P
123	G						G
124	S					ļ	S
125						ļ	1
126	Q					ļ	Ģ.
127	V	ļ					V
128	R						R ₩
129	W						W F
130							
132	L. N						L. N
133	G					ļ	G S
134		<del> </del>	<b></b>			<b></b>	ä
135	Q E	<b></b>	<del> </del>	<b></b>	<b></b>		E
		<b></b>					
136 137	E						<u> </u>
138	A						Å
139	G	·					Ç G
140	V						V
141	V	<b></b>	<b></b>				v v
142			<b></b>			<del></del>	, , , , , , , , , , , , , , , , , , ,
143	S	<b></b>	<b></b>	<b></b>	ļ	<del> </del>	S T
144	N					····	N
145	**********	<b></b>				<del> </del>	
146	L						1
147	R	<b></b>					R
148	N						N N
140	1 54	t	t	1	1	F	1 14

Fig. 118

Position		Di	verse A	mino A	old	•••••	Amino Acid Configuration With Less Tendency to Malignancy
149	G				1	1	G G
150	Ď					İ	Ö
151	W						W
152	Ť	<b></b>	<b></b>				Ť
153	É	ļ	ļ			<del> </del>	
154	Q					<del> </del>	à
155	<u> </u>		<b></b>			·····	i
156	L.						Į.
157	V					<del> </del>	V
158 159	M						M L
	Ļ.						
160	E						E
161	M					ļ	M
162	Ţ	ļ	ļ			ļ	Ţ
163	P		ļ			ļ	P
164	Q					ļ	Q
165	Q	ļ		ļ	ļ	ļ	Q
166	G		ļ			ļ	<u> </u>
167	Q						0
168	V						V
169	Y						Y
170		T					()
171	C						<u>C</u>
172	Q						Q
173	V						V
174	E						E
175	Н	·	·				H
176	T		<b></b>				Ť
177	S			1			S
178	L	M	<u> </u>	<del> </del>			O .
179				<b></b>		1	Ď
180	D S						D 8
181	P	<u> </u>	·····			·	P
182	v	······	······	<b></b>	·····	<del> </del>	v v
183	Ť						
184	Ÿ					<del> </del>	· · · · · · · · · · · · · · · · · · ·
185	E						E
186	W	····				<del> </del>	W
		ļ				<b></b>	
187	K		ļ			ļ	K
188	A						A
189	Ğ	ļ					<u>Q</u>
190	S	ļ					\$
191	D				ļ	ļ	<u>O</u>
192	S	<b></b>	ļ	ļ	ļ	ļ	5
193	Α		ļ			ļ	<u>A</u>
194	R		ļ				R
195	S						\$
196	ĸ						K
197	T						Ť
198	Ļ						L.
199	T						T
200	G		T			T	G
201	Α				T	T	A
202	G	·	<b></b>	1	1	1	A G
203	G		l		1	1	G
204	F		·	1	1	<b>†</b>	F
205	ÿ						v
206	L	<b></b>	<b></b>	<b>†</b>		<u> </u>	Ł
207	G	<b></b>	<b>!</b>	<del> </del>	<del> </del>	<del> </del>	G
441	<u> </u>	t	<u></u>	1	1	Ł	

Fig. 119

Position	C	Diverse Amino Acid	Amino Acid Configuration With Less Tendency to Malignancy
208	L.		
209			I .
210	-		1
211	C		C
212	G		G
213	V		V
214	G		G
215			Į.
216	F		F
217	M		₩
218	Н		H
219	R		R
220	R		R
221	S		\$
222	K		K
223	K		K
224	٧		V
225	Q		Q
226	R		R
227	G		G
228	S		S
229	Α		Α

Fig. 120

Position		Di	verse A	mino A	cid	Amino Acid Configuration With Less Tendency to Malignancy
_32	M			1	1	 M
31	S	<b></b>		<del> </del>	<del>  </del>	 S
30	W				<del> </del>	 W
29	K	<del></del>	<b></b>	<del> </del>	<del>  </del>	 
28	K				<del>  </del>	 K
_27	A	S		<del> </del>	1	
26	<del></del>		<b></b>	<del> </del>	<del>  </del>	 <u>Q</u>
25	Ŕ				1	 <u> </u>
24					1	 ,
	p					 P
_23	G				<del> </del>	 G
21	D	G			<del> </del>	 φ
_20	<u>_</u>				ļ	 <u>.</u>
19	R	V				 Ŕ
18	A				ļ	 Q.
_17	A				ļ	 A
16	Ţ			ļ	ļ	
15	Ā				1	 <u>V</u>
14	T					 T
13	L	ļ			1	 <u></u>
12	M	ļ			ļ	 M
11	L					 <u> </u>
10	A	S				 ()
9		M				 ()
8	L	<u> </u>			1	 <u> </u>
7	S	<u> </u>				 S .
_6	S	T				()
_5	L.	Р	\$			()
_4	L	V				()
_3	A					A
_2	E G					<u>E</u>
	G					G
1	R					R
2	D					D
3	P	S				
4	P					<u> </u>
5	E					
6	D					D D
7	F					F
8	V				1	 V
9	F	Ł.	Y			()
10	Q				1	 Q
11	F	·			1	 
12	ĸ	·			<del>  </del>	 ĸ
13	A	G		<b></b>	<del>  </del>	 j j
14	Ĺ	M	<b></b>	<b> </b>	<del> </del>	 <u> </u>
15	Ç	· · · · · ·			1	 Č
16	Ÿ	<b>!</b>			1	 C Y
17	F				1	 <u> </u>
18	Ť				1	 Ţ
19	N			<del> </del>	1	 N N
20		<b></b>	<b></b>	<del> </del>	<del> </del>	 C N
21	G T	<b></b>	<b></b>	<del> </del>	<del> </del>	 G T
<del></del>		ļ			<del> </del>	 
22 23	E L	R	ļ		<del>  </del>	 E C
	<u></u>	<u> </u>			<del> </del>	 0
24	γ				1	 <u> </u>
25	R	ļ			ļ	 R
26	G	Ł	Y		1	 0
27	У	L	L	1	1	 V

Fig. 121

Position		Di	verse A	mino A	old	••••••	Amino Acid Configuration With Less Tendency to Malignancy
28	S	T					S or ()
29	R						R
30	Н	ŝ	Y				()
31	<b>—</b>						\(\frac{1}{2}\)
32	Ÿ						Ý
33	N						Ň
34	R						Ř
35	Ē						Ē
36	Ē						Ë
37	Ď	1	Y				()
38	A	Ÿ	·····				Û
39	R	·					Ř
40	F						F
41	D						D
42	S						Š
43	Ď						Ď
44	V						V
45	É	G					Ö
46	Ē	V					()
47	F	Ý					
48	R	<u> </u>					Ř
49	A						À
50	V						- V
51	Ť						Ť
52	<u> </u>	p					
53	1	Q					χ
54	Ğ						() G
55	L	Р	R				
56		Р	- 5.4				Ö
57	L A	D	\$	V			0
58	7	<u> </u>		<u>v</u>			Q
59	A E						A E
60	Ÿ						<u> </u>
61	ŵ						w
62	N						N
63	S						\$
64	a						Q
65	K						ĸ
66	a	=					
67	<u> </u>	E V					()
68		, , , , , , , , , , , , , , , , , , ,					
69	E						L E
70	Ē		R				
71	Ā	G D	K	T			<u> </u>
72	R	<u> </u>		<del> </del>			() R
73	A		<b></b>				
		=	-				A
74 75	A	E V	S				<u> </u>
76	L C	V					0
77	D R	Ŧ					D
	17						()
78 79	V C						Ž.
	R						Ċ R
80	<u></u>			ļ	ļ		Ţ.
81	H						H
82	N Y						N Y
83	Y				ļ		Y
84	E	Q					Δ.
85	L	V					()
86	Α	ε	G	L	L		EG

Fig. 122

Position		Di	verse A	mino Acid	••••••	Amino Acid Configuration With Less Tendency to Malignancy
87	F	Ĺ.	Υ			()
88	R					Ř
89	G	Ŧ				()
90	⊢Ť	Ť		<b></b>		l Ö
91	Ĺ.	ļ				<u> </u>
92	Q			<del> </del>		<u> </u>
93	Ř					Ř
94	Ŕ	<b></b>				R
95		<b></b>				V
	V					
96	E P					E P
97						
98						Ţ
99	V					<u>V</u>
100	T	ļ				Ţ
101		ļ				
102	S					S
103	Р			L		p
104	S			L		\$
105	R					R
106	T					T
107	E					£
108	Α					А
109	L					Ł
110	N					N
111	Н	······				H
112	Н	·				<del>,</del>
113	N	·				N
114	L.	<b></b>				i
115	L.	<u> </u>				L.
116	1	V				0
117		<u>`</u>				<u> </u>
118	C S					<u>C</u> 8
119	V					- V
120	Ť					Ť
	D					
121	F					<u>D</u>
122		ļ				
123	Y					Y
124	þ	ļ <u>.</u>				P
125	A	G Q	S			()
126	H	Q				0
127						
128	К			ļ		<u>K</u>
129	V			L		V
130	Q	R		L		()
131	W					W
132	۴					F
133	R					3
134	N					N
135	D					D
136	Q					Q
137	E					
138	E					E E T
139	Ť	<b></b>				T
140	À	7				Ö
141	G	<del></del>				Ğ
142	- Ŭ			<del>  </del>		Ž
143	V			<del>  </del>		v
144				<del> </del>		S
	S			<del> </del>		5 ▼
145	T	E	l	L		

Fig. 123

Position		Di	verse Am	ino Acid	••••••	Amino Acid Configuration With Less Tendency to Malignancy
146	р				T	p
147	L					Ę.
148	1					I
149	R					Ř
150	N					N
151	Ĝ					Ğ
152	Ď	·				D
153	W		<b></b>			w w
154	Ť					<del>'</del>
155	Ė					F
156	Q					Q Q
157	ī				-	i i
158	<u> </u>					<u>.</u>
159	V.					Ž V
160	M					N N
161	L	ļ				L.
		ļ				
162	E		<del>  -</del>			E
163	M					M
164	T					T P
165	P		<b> </b>			
166	Q					۵
167	H	R				<u>Q</u>
168	G					G
169	D					D
170	V	ļ				<u>V</u>
171	Y	ļ				Y
172	T					T
173	C					C
174	H					H
175	V					V
176	E					ш
177	Н					H
178	P					P
179	S					S
180	L					L
181	Q					Q
182	73	S				0
183	a					ρ
184						1
185	)	T				()
186	V					У
187	E					Ë
188	W					W
189	R					R
190	Α					A
191	Q					Q
192	\$					\$
193	E					Ë
194	S					S
195	Ā				1	Ā
196	Q					Q
197	N	S	<b> </b>		-	Ò
198	K	<u>-</u>	<u> </u>			ł K
199	M	<b></b>	·			M
200	L.	<b></b>	<del> </del> -			L COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN COLUMN
201	S		<b></b>			\$
202	G		<del>  -</del>			
202	1	V	<del> </del>			()
203	G	- V				G G
444	<u> </u>	t	L			I ————————————————————————————————————

Fig. 124

Position	•••••	Di	verse Amino Acid	Amino Acid Configuration With Less Tendency to Malignancy
205	G			G
206	۶			F
207	V			V
208	L			L.
209	G			G
210	L			Ł
211	1			
212	F			F
213	L			L.
214	G			G
215	L			L.
216	G			G
217	L			Ł,
218	1			ı
219	1			l l
220	H	R		()
221	Н	a		Ö
222	R			R
223	\$			S
224	Q	R		()
225	К			К
226	G			G
227	P			P
228	Q			Q
229	G			G
230	P			P
231	P			P
232	p			p
233	Α			A
234	G			G
235	L			L.
236	L			L.
237	H			H

Fig. 125

Position	Diverse Amino Acid						Amino Acid Configuration to Inhibit Metastases	Amino Acid Configuration to Inhibit Metastases
_29	M	1	- 0				M	M
_28	V	1					V	V
27							ć	ć
26	C L			<del> </del>			Ĭ	<u> </u>
		<del></del>		ļ				
25	K	R		ļ			Q	<u>Q</u>
24	F	L		L			0	0
23	ρ	1					P	P
_22	G						G	G
_21	G						G	G
20	S			-			\$	s
19	G S C						9 8 0	G S C
18	M						M	M
		T		ļ				
17	Α			ļ			0	0
_16	Α	V		L			0	()
_15	L	1		L			<u>L</u>	<u>L</u>
14	T						T	T
13	V	1		I			V	V
12	Ť	1		1			Υ	Ť
11	L			<del> </del>			L.	L.
10	M	<del> </del>		<del> </del>			M	M
9	V			ļ			V	V
_ <u>8</u> 7	L						L	L
_7	S						S	S
6	S	1		1				S
_5		·····		<del> </del>			8 P	S
4	ί			<del> </del>			i	i i
		ļ		<del> </del>		·····		~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
3	A	ļ					Α	A
_2	L						<u>L</u>	L
	A	S					0	0
1	G						Ğ	G
3	D T						D T	<u>D</u>
3	Ť			1			Ţ	T T
4	à	R		<del> </del>			Ò	Ò
5	P	<del> </del>		<del> </del>			P	P
6	R			ļ			R	R
7	F						F	P
8	L.		- 1				Ĺ	L
9	E	K	W				()	0
10	E	Q	Y	1			Ö	()
11	D	G	£	P	\$	V	()	Ó
12	K	Ť	-	1	<u> </u>	<u> </u>	ŏ	ŏ
13	F	Ġ	H	R	S	~~~		FF or GR
	<u> </u>			<del> </del>		ļ	Ω	
14	Ē C	K		ļ			<u> </u>	<u> </u>
15	C			ļ			С	
16	Н	Q	Υ	L			()	YY
17	F	1					F	F
18	F						F	F
19	N	1		1			Ň	N
20	G						6	G
20	T						Ť	Ť
21								<u> </u>
22	E R	<b> </b>		ļ		ļ	E R	E R
23	R						R	R
24	V	1					V	V
25	Q	R		T			()	0
26	F	T.	Υ	1		·	Ŏ	ŏ
27		<del> </del>		<del> </del>		·		
41	L <sub>D</sub>	<del></del>					<u>L</u>	L.
28	D	E	Н	ļ	ļ		<u>O</u>	Ω
29	R		- 3				R	R
30	0	G	н	L	R	Y	0	0

Fig. 126

Position		Div	erse A	mino /	Acid		Amino Acid Configuration to Inhibit Metastases	Amino Acid Configuration to Inhibit Metastases
31	F	1	V				()	()
32	Н	Y		1			()	Ö
33	H	N		<b>†</b>			Ò	พ่พ
34	Q	<del> </del>		·			ď	ä
35	Ē	<del> </del>		<del> </del>			Ë	Ē
36	Ē	<del> </del>		<del> </del>		·	Ē	Ē
37	F	L	N	S	Y		Ō	Ö
38	A	tt	V	<del>├</del> ───			<u> </u>	<b>1</b>
39		<del> </del>	*	<del> </del>			× ×	Ř
40	R	<del>  γ</del>				·		
41	D	ļ <sup>5</sup>					0	D D
	S			-			S	s
42	0	ļ				ļ	Ď	D
43		<del> </del>						
44	<u> </u>	ļ		ļ			<u>V</u>	V
45	G	<b></b>		ļ		ļ	G	G
46	ε	1		ļ		ļ	E	E
47	۴	Y		ļ	ļ	ļ	Ω	Ω
48	R	<u> </u>		ļ			R	R
49	Α						À	A
50	V						V	V
51	T						Ť	Ť
52	Ε						£	ш
53	L						L	Ł
54	G	1					G	G
55	R	1		1			R	R
56	P	1		1			P	Р
57	A	D	5	T V			()	()
58	A	ε	-	<u> </u>			0	0
59	€	1		<u> </u>			Ĕ	Ě
60	H	s	Υ	-			ō	0
61	W	<del> </del>	<u>'</u>	<u> </u>	<b></b>		Ŵ	
62	N	<del> </del>					N	i i
63	S	<del> </del>					<del>S</del>	s s
64	Q	<del> </del>		<del> </del>		·	ă	ă
65	K	<del> </del>		<del> </del>		<b></b>	K	K
66	8	<del> </del>		ļ		ļ	0	D
67	F	-		ļ				
		1	L				Ω	Q.
68	<u></u>	ļ		ļ			<u>L</u>	<u> </u>
69	E	ļ <u>-</u>		ļ			<u> </u>	E
70	D	Q	R				Q	0
71	_ <u>A</u>	E	K	R			<u>Q</u>	<u>Q</u>
72	Ŗ	ļ <u>.</u>		ļ		ļ	Ŗ	R
73	A	G		ļ <u>.</u>	ļ <u>.</u>	ļ	<u>Q</u>	Ω
74	A	E	L	Q	R	ļ	<u>Q</u>	0
75	V	ļ		ļ		ļ	V	<u>V</u>
76	D	<b></b>		ļ			D	D
77	N	T					0	0
78	٧	Y					0	0
79	C						C	C
80	R						R	R
81	늰	1					H	H
82	N			L			N	N
83	Y	1		Ι			Y	Y
84	Ğ	1		1	1		G	G
85	A	V		T			0	0
86	G	ÍV	1	1	1		Ö	Ŏ
87	Ē	<del>                                     </del>		<b></b>			¥ £	Ě
88	S	1		1	1		\$	Š
89	F	1		<b></b>			F	F
~ ·	L	1	1	£	.K	h	·	

Fig. 127

Position	Diverse Amino Acid						Amino Acid Configuration to Inhibit Metastases	Amino Acid Configuration to Inhibit Metastases
90	T	1					Υ	r
91	V	1					V	V
92			1	<b>†</b>			á	ά
93	Q R	<del> </del>		·			Ř	Ř
94	R	<del> </del>		<del> </del>			Ř	Ŕ
95	<del>'</del>	ļ		ļ		ļ	Ÿ	<del>                                     </del>
		<del> </del>		ļ;		ļ	<b></b>	-4
96	E	Н	Q	Υ			Ω	<u>Q</u>
97	ρ	ļ		L		L	P	P
98	€	K					00	0
99	V						V	V
100	Ť						Ť	Ť
101	V						V	V
102	Y	<del> </del>					Ÿ	Ť Ž
103	è	<del>}</del>	<del> </del>			<del> </del>	è	P
104	A	S						
		1-3-	ļ	ļ	ļ	ļ	9	9
105	K		ļ	ļ			K	K
106	T	<b></b>		L			Ţ	T
107	Q	L	L	L			a	a
108	Р						P	P
109	L	1					L	L
110	Q	1	1	1		<b></b>	ā	ā
111	H		1	<b>†</b>			н	H
112	H			<del> </del>		ļ	<u> </u>	H
		ļ		ļ			H	
113	N	ļ		ļ		ļ	N	N
114	L	1		L			L	L.
115	L			L		<u> </u>	<u>L</u>	L
116	V						V	V
117	C						C	C
118	S	1					S	s
119	V	1	1			1	v	V
120		\$		<del> </del>				
	N F	1					<u>Q</u>	<u>Q</u>
121		ļ		ļ		ļ	F	F
122	G			ļ			G	Ğ
123	Y						Y	Y
124	P	1		<u> </u>		l	P	P
125	G						G	G
126	\$	1					S	S
127		1	1	1		·	1	
128		<del> </del>		1		·	Ë	E
	E V			ļ			Ÿ	† v
129								
130	R			ļ			<u>R</u>	<u>R</u>
131	W			ļ			W	W
132	F			L		<u> </u>	F	F
133	L	R		L			()	()
134	N	1				1	N	N
135	G	1		T		<u> </u>	G	G
136	Q	1		<u> </u>	1	<b> </b>	Ŏ.	Q
137	E	1		<u> </u>			Ē	Ē
	- =						<u> </u>	<u> </u>
138	£						<u> </u>	<u> </u>
139	K						K	K
140	Α	T	L	L			() G	<u>)</u> G
141	G	1		L		L	G	G
142	M	V		1		[	()	()
143	V	1	1	1	1	·	Ÿ	V
144	Š	1	1	<b>†</b>		<b>†</b>	Š	1 8
145	Ť	<del> </del>	<b></b>	<del> </del>		<del> </del>	Ť	S
							1	<u> </u>
146	G	ļ	ļ	ļ		ļ	G	G
147	L						Ĺ	Į.
148	1		1				1	

Fig. 128

Position	Diverse Amino Acid					······	Amino Acid Configuration to Inhibit Metastases	Amino Acid Configuration to Inhibit Metastases	
149	H	a			1		()	0	
150	N						N N	N N	
151	G						N G	Ğ	
		ļ					D B	D D	
152	D								
153	W	ļ					W	W	
154	T	ļ					Ŧ	Ť	
155	F						F	F	
156	Q						Q	Q	
157	T						Ţ	Ť	
158								£	
159	L V	-				********	r r	V	
160	M						M	M	
161	L				<b></b>	~~~~	i.		
~~~~~									
162	E						E	<u>E</u>	
163	Ī	ļ	ļ	ļ	ļl		Ī	Ţ	
164	F	V					()	0	
165	P				1		P	P	
166	Q	R					()	0	
167	S						S	\$	
168	G						Ğ	Ġ	
169	Ε	1					Ë	E	
170	V						V V	<u>-</u>	
171	Y					·····	Y	<u>Y</u>	
172	T	L					T	T	
173	C						С	C	
174	Q						Q	Q	
175	V						V	V	
176	E						E	£	
177	H						H	H	
178	P						P	P	
179	S								
							S	9	
160	L	V					<u>Q</u>	<u> </u>	
181	M	T					0	<u> </u>	
182	S					~~~~~	] S	\$	
183	P						P	Þ	
184	L						L.	Ł	
185	T						T	T	
186	V						V	V	
187	ε						É	Ė	
188	W		·				w	<del>-</del>	
189	R	S		-					
***************************************	********				ļļ	~~~~	()	Q	
190	A						<u>A</u>	A	
191	R	ļ					R	Ř	
192	S						S	S	
193	Ε					·····	E S	E S	
194	S						\$	S	
195	A						A	A	
196	Q						Q	Q	
197	S						S	- S	
198	ĸ	·					K	K	
199	M				<b></b>		M N	M	
198					<b></b>		101	371	
200	L				ļl		<u> </u>		
201	S	ļ	ļ		ļl		L S G	S G	
202	G						G	G	
203	٧						V	V	
204	G		[				G	Ğ	
205	G						G	G	
206	F		<b></b>				F	F	
207	v						v	, V	
7 كدايت	ł Y	t	F	1 .	F		*	ø.	

Fig. 129

Position	•••••	Di	verse Amino Acid	Amino Acid Configuration to Inhibit Metastases	Amino Acid Configuration to Inhibit Metastases L
208	L			L	
209	G			G	G
210	L			L	Ł.
211	L			L	L
212	F			F	F
213	L			L	L
214	G			G	G
215	Α			A	A
216	G			G	G
217	L			L	L.
218	F			F	F
219	1				ı
220	Y			Y	Y
221	£			F	F
222	R			R	R
223	N			N	N
224	Q			Q	Q
225	K			K	К
226	G			G	G
227	Н			н	Н
228	S			S	S
229	G			G	G
230	L			L	L
231	P	Q		()	0
232	P			P	P
233	R	Ŧ		()	()
234	G			G	G
235	۴			F	F
236	L			L.	L.
237	S			S	S